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ABSTRACT 
The biological and chemical diversity of protein structure and function can be 
greatly expanded by position-specific incorporation of non-natural amino acids bearing a 
variety of functional groups. Non-cognate amino acids can be incorporated into proteins 
at specific sites by using orthogonal aminoacyl-tRNA synthetase/tRNA pairs in 
conjunction with nonsense, rare, or 4-bp codons. There has been considerable progress in 
developing new types of amino acids, in identifying novel methods of tRNA 
aminoacylation, and in expanding the genetic code to direct their position.  
 Chemical aminoacylation of tRNAs is accomplished by acylation and ligation of a 
dinucleotide (pdCpA) to the 3ʹ′-terminus of truncated tRNA. This strategy allows the 
incorporation of a wide range of natural and unnatural amino acids into pre-determined 
sites, thereby facilitating the study of structure-function relationships in proteins and 
allowing the investigation of their biological, biochemical and biophysical properties.    
 Described in Chapter 1 is the current methodology for synthesizing aminoacylated 
suppressor tRNAs. Aminoacylated suppressor tRNACUAs are typically prepared by 
linking pre-aminoacylated dinucleotides (aminoacyl-pdCpAs) to 74 nucleotide (nt) 
truncated tRNAs (tRNA-COH) via a T4 RNA ligase mediated reaction. Alternatively, 
there is another route outlined in Chapter 1 that utilizes a different pre-aminoacylated 
dinucleotide, AppA. This dinucleotide has been shown to be a suitable substrate for T4 
RNA ligase mediated coupling with abbreviated tRNA-COHs for production of 76 nt 
aminoacyl-tRNACUAs. The synthesized suppressor tRNAs have been shown to participate 
in protein synthesis in vitro, in an S30 (E. coli) coupled transcription-translation system 
in which there is a UAG codon in the mRNA at the position corresponding to Val10. 
 ii 
 Chapter 2 describes the synthesis of two non-proteinogenic amino acids, L-
thiothreonine and L-allo-thiothreonine, and their incorporation into predetermined 
positions of a catalytically competent dihydrofolate reductase (DHFR) analogue lacking 
cysteine. Here, the elaborated proteins were site-specifically derivitized with a 
fluorophore at the thiothreonine residue. 
 The synthesis and incorporation of phosphorotyrosine derivatives into DHFR is 
illustrated in Chapter 3. Three different phosphorylated tyrosine derivatives were 
prepared: bis-nitrobenzylphosphoro-L-tyrosine, nitrobenzylphosphoro-L-tyrosine, and 
phosphoro-L-tyrosine. Their ability to participate in a protein synthesis system was also 
evaluated.  
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CHAPTER 1 
INTRODUCTION 
 
1.1. Protein biosynthesis 
Proteins are biochemical macromolecules that play a central role in a vast array of 
biological processes in living organisms; they catalyze metabolic reactions, transport 
molecules within cells, replicate DNA, and perform many other vital functions. Proteins 
contain one or more chains of amino acids (polypeptides) that are folded into specific 
three-dimensional shapes. In most cases, the identity and position of the amino acid 
residues and their side chains within a protein determine its properties and function.  
Protein biosynthesis is the process by which cells generate new proteins. The 
biosynthetic pathway for proteins involves a number of events including transcription of 
nuclear DNA to mRNA, translation of mRNA, and polymerization of amino acids to 
afford protein products. Protein synthesis is carried out by an elegant complex composed 
of the ribosome and several accessory protein factors, as well as mRNA and 
aminoacylated tRNA molecules. All ribosomes are comprised of two subunits of unequal 
size. In E. coli, the small subunit is referred to as the 30S subunit, while the large subunit 
is called the 50S subunit. Together, these subunits are responsible for decoding the 
genetic message and catalyzing peptide bond formation.1 It has recently been shown that 
mutation of the 50S subunit, specifically the 23S component, can affect the ability of the 
ribosomal machinery to accommodate β-L-amino and D-amino acids for incorporation 
into nascent polypeptides.2-4  
Protein translation proceeds via four distinct steps, namely, (1) tRNA activation, 
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(2) initiation of translation, (3) peptide elongation, and (4) peptide termination. tRNA 
molecules are the decoders of genetic information. tRNAs provide the link between the 
sequence of nucleotides in mRNA and the resulting sequence of amino acids in a 
polypeptide.  Every cell contains at least 20 tRNA molecules, one for each naturally 
occurring amino acid, and each tRNA recognizes at least one codon (triplet sequence) in 
the genetic code. In an aminoacylation event (tRNA activation), a particular amino acid is 
covalently attached to the 3ʹ′ end of a tRNA molecule by means of an aminoacyl-tRNA 
synthetase (aaRS) and ATP. Aminoacylation proceeds in two discrete steps. First, an 
amino acid is activated by the formation of a reactive aminoacyl-adenylate intermediate. 
The intermediate is tightly (but non-covalently) bound to the aminoacyl-tRNA 
synthetase. Subsequent hydrolysis of pyrophosphate promotes an essentially irreversible 
reaction. Next, the aminoacyl group is transferred from the intermediate to tRNA. Upon 
binding to its cognate tRNA, the amino acid is transferred to either the 2ʹ′ or 3ʹ′-OH group 
of the terminal adenylate residue of tRNA, depending on the specific synthetase 
catalyzing the reaction. There are two classes of aminoacyl-tRNA synthetases, class I and 
class II, that aminoacylate the A76 2ʹ′- or 3ʹ′-OH group of the tRNA, respectively. If the 
amino acid is initially attached to the 2ʹ′-OH of the tRNA, it will ultimately migrate to 
afford a 3ʹ′-O-acyl isomer that can serve as a substrate for protein synthesis.5  
Initiation of protein synthesis involves the formation of a translation complex at 
the beginning of the mRNA coding sequence. The complex contains the ribosomal 
subunits, the mRNA template, an initiation tRNA molecule, and several accessory protein 
initiation factors. The first codon translated is typically AUG. Every cell contains at least  
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two methionyl-tRNAMet molecules that recognize the AUG codon, one of which is 
used exclusively at initiation codons and is referred to as the initiator tRNA. In 
prokaryotes, the 30S ribosomal subunit binds to the mRNA at a purine-rich region of the 
mRNA template just upstream of the initiation codon. This region, referred to as the 
Shine-Dalgarno sequence, is complementary to a pyrimidine-rich region at the 3ʹ′ end of 
the 16S rRNA component. Formation of the initiation complex requires several initiation 
factors; prokaryotes contain 3 factors whose role is to ensure that the aminoacylated 
initiator tRNA is correctly positioned at the initiation codon. 
At the close of the initiation step, the mRNA is positioned such that the next 
codon can be translated during the elongation stage of protein synthesis. The elongation 
cycle can be summarized by three major events, (1) codon recognition, (2) peptide bond 
formation and (3) translocation, which are assisted by elongation factors. The recognition 
event between the next codon in the mRNA and the anti-codon loop of the corresponding 
aminoacylated tRNA results in binding of the tRNA to the A-site of the ribosome, and 
transfer of the amino acid from the tRNA in the P-site to the tRNA transiently bound in 
the A-site. The subsequent translocation event results in movement of the tRNAs in the 
A- and P-sites to the P- and E-sites, respectively. The next aminoacylated-tRNA, 
corresponding to the next codon in the mRNA, then binds to the vacant A-site. 
Elongation proceeds until termination is signaled by the presence of any one of three stop 
codons: UAG, UAA and UGA. The presence of stop codons in the ribosomal A-site 
initiates binding of protein release factors due to the lack of cognate tRNAs present in the 
cell. These factors trigger the release of the nascent polypeptide from the ribosome and 
the dissociation of the ribosomal subunits.6  
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1.2. Suppressor tRNA technology 
There are several methods that can be used to circumvent the termination event, 
including mRNA frame-shifting and the use of modified or cellular tRNAs capable of 
recognizing stop codons (natural suppressors). A suppression event refers to translation 
of a stop codon, thereby circumventing the effect of release factors that signal the 
termination of protein synthesis in the ribosome. Goodman and co-workers realized that 
the genetic code could be expanded by suppressing the UAG stop codon via modification 
of the nucleobases of a tyrosyl-tRNA anticodon loop. Briefly, the authors illustrated that 
mutation of the suIII gene changed the anticodon loop of a minor Tyr-tRNA species in E. 
coli from GUA to CUA. They demonstrated that the amino acid tyrosine could be 
inserted into a protein by suppressing the UAG stop codon.7 Ten years later Hecht and 
co-workers pioneered the “chemical aminoacylation” of tRNAs, signifying a 
breakthrough in in vitro protein synthesis.8 Here, a nitrophenylsulfenyl-N-protected 
amino acid was used to aminoacylate a P1,P2-bis(5ʹ′-adenosyl)diphosphate, which was 
subsequently ligated (by T4 RNA ligase) to a truncated tRNA lacking the terminal 3ʹ′-
adenosine moiety. This technology has allowed researchers to mis-aminoacylate tRNAs, 
i.e. attach a variety of natural and unnatural amino acids to non-cognate tRNAs, 
potentially enabling the preparation of proteins containing non-proteinogenic amino 
acids. Several years later Hecht and co-workers improved upon this methodology by 
aminoacylating a dinucleotide, pCpA, with an N-protected amino acid and enzymatically 
ligating the aminoacylated dinucleotide to a 74 nucleotide tRNA (tRNA-COH) lacking the 
terminal two nucleotides at the 3ʹ′-end. However, because the aminoacyl-tRNA contained 
an N-protected amino acid they could not be used to produce modified proteins.9 N-acetyl 
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protection of the amino group precludes the ability of misacylated tRNAs to be accepted 
in the A-site. Brunner and co-workers circumvented this problem by protecting the amine 
as a di-tert-butoxycarbonyl (t-Boc) derivative, which is an acid labile protecting group 
typically removed with trifluoroacetic acid (TFA).10 Unfortunately, the preparation and 
subsequent aminoacylation of the dinucleotide afforded only modest amounts of 3ʹ′-O-
aminoacylated pCpA. In an effort to overcome this issue, Schultz and co-workers 
prepared a deoxycytidine dinucleotide, pdCpA, which not only simplified the synthesis of 
the dinucleotide but also enhanced aminoacylation yields.11 pdCpA is now widely used 
for preparing mono-aminoacylated tRNACUAs, a suppressor tRNA bearing one amino 
acid.  
Interestingly, Stepanov and co-workers described the ability of a phenylalanyl-
tRNA synthetase to attach two phenylalanine amino acids onto the 3ʹ′-end of its cognate 
tRNA.12,13 However, the ability of the doubly charged tRNAs ability to participate in 
protein biosynthesis was not studied, nor well understood. The Hecht laboratory later 
demonstrated the ability of bisaminoacylated tRNAs to participate in protein synthesis.14-
16 The ability of bisaminoacylated tRNAs to function in protein synthesis suggests that 
the prokaryotic elongation factor EF-Tu•GTP is not only capable of recognizing tRNAs 
with two amino acids attached, but also of binding to and translocating tRNA from the 
cytoplasm to the ribosomal A-site. Additionally, they demonstrated that the nascent 
polypeptide, bound to tRNA in the P-site, is transferred to the aminoacyl moeity at the 3ʹ′-
position of the bisaminoacylated tRNACUA in the A-site. They demonstrated this by 
utilizing a bisaminoacylated tRNA bearing two different amino acids at the 2ʹ′- and 3ʹ′-
positions of the adenosyl-ribose.17,18  
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CHAPTER 2 
A NEW STRATEGY FOR THE SYNTHESIS 
OF BISAMINOACYLATED tRNAs 
 
2.1. Introduction 
Chemically aminoacylated suppressor tRNAs have allowed the introduction of 
various natural and non-natural amino acids into proteins at pre-determined sites as 
illustrated in Figure 2.1.19-21  
 
 
Figure 2.1. Utilization of tRNACUAs for protein elaboration. 
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 Briefly, a UAG stop codon is introduced at a desired position within a gene of 
interest by oligonucleotide site-directed mutagenesis, and the gene is subsequently 
inserted into a plasmid expression vector.20,22 Similarly, a gene coding for a 
complementary phenylalanyl-tRNA, containing an anticodon loop that recognizes and 
binds to the UAG codon in the modified mRNA, is inserted into an expression vector. 
Transcription of both plasmids results in the production of modified mRNA and 
tRNACUA. When used together in a cell free protein synthesis system, the aminoacylated 
tRNACUA binds to the stop codon, suppresses any release factors, and enables peptide 
elongation to continue.9,16,20,22-25  
This strategy has facilitated study of the biochemical and biophysical properties 
of numerous proteins.7,26 While monoaminoacylated tRNAs are ordinarily used in protein 
synthesis systems, Lavrik and co-workers described a phenylalanyl-tRNA synthetase 
from Thermus thermophilus that incorporates more than one molecule of phenylalanine 
into tRNAPhe, producing bis-(2',3'-O-phenylalanyl)-tRNAs.12,13 It is notable that 
bisaminoacylated tRNAs exhibit higher chemical stability than their monoaminoacylated 
tRNA counterparts (Figure 2.2), and are able to participate in two cycles of peptide bond 
formation (Figure 2.3).14-16,24  
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Figure 2.2. Relative stabilities of mono- and bisaminoacylated tRNA models.15  
 
 In the presence of two different nucleophiles, butylamine and imidazole, 
bisaminoacylated pdCpAs, which may be regarded as models for bisaminoacyl-tRNAs, 
were converted to their deacetylated derivatives much more slowly than the 
corresponding monoaminoacylated molecules (Figure 2.2).  
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Figure 2.3. Utilization of bisaminoacylated tRNACUAs in protein synthesis.15  
 
In addition, under synthesis conditions that are limiting for aminoacylated 
suppressor tRNAs, twice as much protein is expressed when utilizing bisaminoacylated 
tRNACUAs.17 Considering these results, it is reasonable to assume that the advantages of 
bisaminoacylated tRNACUAs can be exploited for in vitro translation experiments and 
other protein studies. It is important to note that preparation of suppressor tRNAs bearing 
two amino acids is dependent on the preparation of the corresponding dinucleotide 
precursors. The synthesis of bisaminoacylated pdCpA bearing amino acids with relatively 
small side chains is expected to proceed in reasonable yield. However, it seems likely that 
steric bulk from the nitrogenous bases of the dinucleotide, together with the amino acid 
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side chains, will hinder the preparation of bisaminoacylated pdCpAs with amino acids 
having large side chains.27 Careful consideration and revision of the methodology could 
facilitate general use of this technology and lead to the production of suppressor tRNAs 
bearing two non-natural amino acids with large side chains.  
The proposed strategy to expand the production bisaminoacylated derivatives of 
pdCpA described herein is based on a ‘chemical aminoacylation’ technology reported by 
Hecht and co-workers.8 Hecht demonstrated that a nitrophenylsulfenyl-N-protected 
amino acid could be used to aminoacylate a P1,P2-bis(5ʹ′-adenosyl)diphosphate. The 
aminoacylated dinucleotide was then ligated to a truncated tRNA lacking the terminal 3ʹ′-
adenosine nucleotide by T4 RNA ligase. Based on this result, we predicted that 
bisaminoacylation of 5ʹ′-AMP with amino acids having bulky side chains would proceed 
more easily than pdCpA, and that the resulting bisaminoacylated AMP would still be 
converted to a substrate recognized by T4 RNA ligase for attachment to an abbreviated 
tRNACUA. To test this hypothesis we aminoacylated pdCpA (Figure 2.4) and AMP 
(Figure 2.5) with amino acids bearing relatively large side chains (Figure 2.6) and 
analyzed the relative amount of mono- and bisaminoacylated products.  
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Figure 2.4. Mono- and bisaminoacylated pdCpAs. 
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Figure 2.5. Mono- and bisaminoacylated AMPs. 
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Figure 2.6. Amino acids analogues prepared for aminoacylation of pdCpA and AMP. 
 
2.2. Results 
In order to synthesize aminoacylated tRNAs, the free amino acid must first be 
protected, followed by activation of the carboxylic acid as the cyanomethyl ester. 
Pentenoyl protected amines were prepared from the corresponding free amino acids by 
treatment with 4-pentenoyloxy succinimide ester; the resulting crude products were 
extracted, isolated, and subsequently used without further purification. N-pentenoyl-L-
amino acids were then treated with chloroacetonitrile and triethylamine to yield products 
2.11-2.15, in yields ranging from 56% to 88% (Table 2.1).  
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Table 2.1. Pentenoyl protection and cyanomethyl ester formation of amino acids. 
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Scheme 2.1. Synthesis of mono- and bisaminoacylated-pdCpAs. 
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The syntheses of mono- and bisaminoacylated dinucleotide pdCpAs and 
mononucleotide AMP are illustrated in Schemes 2.1 and 2.2, respectively. Coupling 
amino acids to pdCpA in DMF, in the presence of Et3N, affords the mono- and  in some 
instances bisaminoacylated pdCpAs. The monoaminoacylated derivatives were prepared 
in relatively high yields, 50-84%. However, there were only two amino acids, 
phenylalanine and biphenylalanine, that afforded the bisaminoacylated species. 
Moreover, generation of the bisaminoacylated dinucleotide proceeded in modest yields, 
30% and 40%, respectively. While there are presumably many factors involved in the 
successful production of dinucleotides bearing two amino acids, the steric hindrance 
resulting from the amino acid side chains and the orientation of the dinucleotide are 
certainly relevant. Thus, as the size of the amino acid side chains increased we observed 
the production of fewer bisaminoacylated species. Typically, the reactions were 
monitored by reverse phase HPLC, and purified after the consumption of pdCpA using a 
linear gradient of acetonitrile in 45 mM ammonium acetate (pH 4.5, 45 minutes). 
Collection and lyophilization of the appropriate fractions gave the aminoacylated 
dinucleotide as a white solid. Interestingly, if required, the two pdCpAs isomers (2ʹ′- and 
3ʹ′-aminoacyl pdCpAs) can be separated following a previously described purification 
method.18 
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Scheme 2.2. Synthesis of mono- and bisaminoacylated AMPs. 
  
Utilizing the mono nucleotide adenosine-5ʹ′-monophosphate for aminoacylation 
with amino acids 2.11-2.15 afforded both the mono- and bisaminoacylated nucleotides, 
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regardless of the amino acid side chain, in yields ranging from 67-77%. While the 
aminoacylated dinucleotide pdCpA-aa is a substrate for T4 RNA ligase, the aminoacyl 
AMP analogue is not recognized by the enzyme and must be converted to its AMP 
pyrophosphate derivative, AppA-aa. Treatment of each of the five monoaminoacylated 
species, 2.6a-2.10a, and five bisaminoacylated AMPs, 2.6b-2.10b, with imidazolium 
AMP afforded the respective aminoacylated-AppAs in yields ranging from 81% to 94% 
(Scheme 2.3). Gratifyingly, preparation of a usable substrate for the generation of 
suppressor tRNAs, i.e. aminoacyl-AppA derivatives, did not seem to be affected by 
mono- or bisaminoacylation. 
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Scheme 2.3. Synthesis of mono- and bisaminoacylated AppAs. 
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Preparation of AppA derivatives is dependent on the preparation of imidzaolium 
AMP. AppA derivatives were prepared in a similar fashion as previously reported.28,29 
Generally, the imidazolium derivative is prepared in situ with triphenylphosphine, 4,4ʹ′-
dipyridyl disulfide, triethylamine and methylimidazole. By using imidazole rather than 
the methylated derivative, the reagent could be isolated by precipitation (in 95% yield) 
and stored for future use.  
Suppressor tRNA-COH, in combination with pdCpA, has been used extensively 
for the preparation of misacylated tRNAs.11,17,18,21,25,27,30-32 However, the suppressor 
tRNA-CCOH had never been described, and thus, had to be prepared. Oligonucleotide 
directed mutagenesis of a pYRNA8 plasmid (containing the gene for tRNA-COH) allowed 
the insertion of one nucleotide, T, between the recognition and cleavage sites of 
restriction enzyme FokI (Scheme 2.4). This work was performed by Dr. Shengxi Chen. 
 
Scheme 2.4. Strategy for inserting one nucleotide into a specific position in pYRNA8. 
 S26 
Scheme S1. Strategy for inserting one nucleotide into pYRNA8.
Designed one primer which is one nucleotide longer (RED) than the original sequence. purple is Fok I recognition
site; blue is the nine nucleotides between recognition site and cut site.
5'- CA GAA TTC GCA CCA GGT T GAT CCA TCC AAG CTT GGC GTA-3'
hybridize with plasmid
5'- CA GAA TTC GCA CCA GG AT CCA TCC AAG CTT GGC GTA-3'
3'- GT CTT AAG CGT GGT CCA CTA GGT AGG TTC GAA CCG CAT-5'
T
T G
site-directed mutagenesis
5'- CA GAA TTC GCA CCA GGT T GAT CCA TCC AAG CTT GGC GTA-3'
3'- GT CTT AAG CGT GGT CCA A CTA GGT AGG TTC GAA CCG CAT-5'
Fok I cleavage
5'- CA GAA TTC G\CA CCA GGT T GAT CCA TCC AAG CTT GGC GTA-3'
3'- GT CTT AAG CGT GG\T CCA A CTA GGT AGG TTC GAA CCG CAT-5'
transcription
5'-......GAAUUCGCACC75-3'
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The primer that was used for insertion of the desired nucleotide, 5′-CAG AAT 
TCG CAC CAG GTT GAT CCA TCC AAG CTT GGC GTA A-3′, was incubated with 
ATP and T4 polynucleotide kinase (PNK) so that it would be phosphorylated at the 5′-
end.33 A polymerase chain reaction (PCR) was carried out in a mixture of pYRNA8 
plasmid DNA, phosphorylated primer, dNTPs, Pfu DNA polymerase and Taq DNA 
ligase. Pre-incubation of the mixture at 65 °C for 5 minutes ensured that all nicks in the 
double helices would be repaired by the ligase; the thermal cycle was then carried out, 
followed by a post-incubation hold at 75 °C for 7 minutes. The restriction enzyme DpnI 
was subsequently added to the mixture, which was then incubated at 37 °C for 60 
minutes to eliminate the methylated and hemi-methylated wild type DNA template.  
Ten µL of the final sample was transformed into 100 µL of E. coli competent cell line 
DH5α. Linearization of the mutant plasmid pYRNA8 with FokI to obtain the truncated 
(75 nt) yeast suppressor tRNAPheCUA-CCOH was performed by incubation at 37 °C for 4 
hours. The supernatant was carefully decanted, washed with 70% ethanol, and dried in air 
(Figure 2.7). 
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Figure 2.7. Digestion of mpYRNA8 and pYRNA8 plasmids with FokI. 
 
Transcription of the digested plasmid was carried out with an Ampliscribe T7  
transcription kit containing 7.5 mM each of ATP, CTP, GTP and UTP, 10 mM 
dithiothreitol, linearized DNA template and T7 RNA polymerase. The reaction was run at 
37 °C for 6 hours. Following incubation, the mixture was treated with RNase free DNase 
I and incubated at 37 °C for 15 minutes. Next, the mixture was incubated in 3 M NaOAc 
and ethanol. The DNA was precipitated by incubation at  –20 °C for 30 minutes, 
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Figure S1. Digestion of mutant pYRNA8 plasmid with FokI. 
 
 
 
 
 
 1       2     3
Mu
tan
t p
YR
NA
Mu
tan
t p
YR
NA
 
+ 
Fo
kI
pY
RN
A +
 
Fo
kI
 
 23 
followed by centrifugation (14,000×g for 30 minutes at 4 °C). 
The elaborated tRNA-CCOH transcript was dissolved in 0.1 M NaOAc, pH 5.2, 
and applied to a 400-µL DEAE-Sepharose CL-6B column. The column was subsequently 
washed with 0.1 M NaOAc, pH 5.2. Elution with a sodium chloride gradient afforded the 
desired tRNACUAs . The collected fractions were then treated with 2-propanol, incubated 
at 4 °C for 30 minutes, and centrifuged at 14,000×g for 30 minutes. The pellets were 
washed with 70% ethanol and reconstituted in RNase-free water for subsequent analysis 
in an 8% denaturing polyacrylamide gel (100 V, 2 hours). The fractions (0.6 and 0.7 M 
NaCl) affording the tRNA-CCOH were pooled and stored at –80 °C. (Figure 2.8). 
 
 
 
Figure 2.8. Elution of abbreviated suppressor tRNA-CCOH on a DEAE-Sepharose Cl-6B 
column with NaOAc gradient.  
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Figure S2. Purif cation of the bbreviated suppressor tRNA-CCOH. 
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Mono and bis-aminoacyl-tRNAs were prepared by a T4 RNA ligase-mediated 
ligation reaction between the N-protected, chemically synthesized aminoacylated pdCpA 
derivatives and the abbreviated suppressor tRNA-COH lacking the last two nucleotides at 
the 3ʹ′-end of the tRNA11,22. Similarly, ligation of aminoacylated AppA derivatives 
employed the abbreviated suppressor tRNA-CCOH lacking the last nucleotide, adenosine, 
at the 3ʹ′-end. The ligation reactions were carried out in 100 mM HEPES, pH 7.5, with 
ATP (only in the reaction containing aminoacylated pdCpA derivatives + suppressor 
tRNA-COH), 15 mM MgCl2, the appropriate suppressor tRNA, 2.0 A260 units of N-
pentenoyl- protected mono- or bisaminoacyl-pdCpA or AppA derivatives, 5- to 10-fold 
molar excess, 15% DMSO and T4 RNA ligase. After incubation at 37 °C for 30 minutes, 
the tRNAs were precipitated and dissolved in 50 µL of water. The efficiencies of ligation 
were estimated by denaturing polyacrylamide gel electrophoresis at pH 5.2 (100 V, 2 
hours). Estimating the ligation efficiency for AppA derivatives proved difficult; resolving 
the single nucleotide addition to the abbreviated tRNA and verification of the ligation 
reaction was illustrated through expression experiments. 
Deprotection of suppressor tRNAs was achieved by using I2 (25 mM,1:1 H2O–
THF). The reaction mixtures were incubated at 25 °C for 10 minutes. The tRNAs were 
precipitated by the addition of ethanol and centrifuged at 14,000 × g (30 minutes, 4 °C). 
The supernatants were then carefully decanted and the pellets were washed with 50 µL of 
70% ethanol and then reconstituted in water. 
 In vitro translation reactions were performed using a bacterial S-30 extract from 
E. coli strain BL21(DE3). The reaction mixtures were incubated at 37 °C for 45 minutes.  
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Aliquots from in vitro translation mixtures, employing mono- and bisaminoacylated 
tRNAs prepared from aminoacyl-AppA precursors, were analyzed by SDS-PAGE, as 
shown in Figures 2.9 and 2.10, respectively.  
 
 
Figure 2.9. In vitro synthesis of DHFR utilizing monoacylated tRNACUAs to suppress a 
UAG codon at position 10 of DHFR mRNA. Lane 1, wild-type mRNA; Lanes 2-8, 
modified mRNA; Lane 2, no tRNACUA; lane 3, L-phenylalanyl-tRNACUA (prepared from 
pdCpA); lane 4, L-phenylalanyl-tRNACUA; lane 5, 3,4-dimethoxy-L-phenylalanyl- 
tRNACUA; lane 6, 3-(1-naphthyl)-L-alanyl-tRNACUA; lane 7, 3-(2-naphthyl)-L-alanyl-
tRNACUA; lane 8, L-4,4ʹ′-biphenylalanyl-tRNACUA. 
 
 
Figure 2.10. In vitro synthesis of DHFR utilizing bisaminoacylated tRNACUAs to 
suppress a UAG codon at position 10 of DHFR mRNA. Lane 1, wild-type mRNA; Lanes 
2-8 modified mRNA; lane 2, no tRNACUA; lane 3, L-phenylalanyl-tRNACUA (prepared 
from pdCpA); lane 4, bis-L-phenylalanyl-tRNACUA; lane 5, bis-L-3,4-
dimethoxyphenylalanyl-tRNACUA; lane 6, bis-3-(1-naphthyl)-L-alanyl-tRNACUA; lane 7, 
bis-3-(2-naphthyl)-L-alanyl-tRNACUA; lane 8, bis-L-4,4ʹ′-biphenylalanyl-tRNACUA. 
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Fig. 3 
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Fig. 4 
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2.3. Discussion  
Early studies demonstrated that the dinucleotide pdCpA is capable of being 
esterified at both the 2' and 3'-OH groups to form a bisaminoacyl derivative that can 
ultimately be activated tRNAs in tandem, as outlined in Fig. 2.1.17 Additionally, it was 
shown that bisactivated tRNAs are able to participate in protein synthesis much more 
efficiently than their monoactivated counterparts. When in vitro protein translation 
experiments were carried out under conditions limiting for suppressor tRNA, twice as 
much protein was produced by bisaminoacylated tRNAs than monoaminoacylated 
tRNAs. Additionally, tRNAs bearing two amino acids also exhibit enhanced stability 
compared to their monoaminoacyl counterparts.14-17,24 Molecular modeling studies 
suggest the enhanced stability of the bisaminoacylated tRNAs arises from the interaction 
of a hydronium ion between the aminoacyl moieties and the N-3 of the adenine 
nucleobase.14 
The advantages of bisaminoacylated tRNAs make them attractive compounds for 
use in in vitro and in vivo protein synthesis systems. However, compound B (Schemes 
2.5 and 2.6) is difficult to obtain, as the tRNA is prepared from pdCpAs bearing large 
side chain amino acids. This has prevented the general use of these compounds and 
requires revision. Therefore, it is important to find a more facile route for the production 
of pre-bisaminoacylated dinucleotides capable of ligation to abbreviated suppressor 
tRNAs. 
Misacylated suppressor tRNAs can be prepared by reacting chemically 
aminoacylated pdCpA with tRNAs lacking the 3'-terminal dinucleotide pCpA, via a T4 
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RNA ligase-mediated condensation.11 T4 RNA ligase is an ATP dependent enzyme that 
catalyzes 3'→5' phosphodiester bond formation in RNA. The reaction sequence is 
initiated by a phosphoryl transfer reaction with ATP; in the presence of T4 RNA ligase 
an adenylated enzyme is generated, followed by subsequent transfer of adenosine to an 
RNA donor (pNn) to form a phosphoroanhydride (A5'pp5'N). Finally, the adenylate 
donor reacts with a 3' terminal hydroxyl group of the RNA molecule (abbreviated tRNA) 
to form a 3'→5' phosphodiester linkage. Hecht and co-workers first described “chemical 
aminoacylation” in which the phosphoroanhydride intermediate of the T4 reaction was 
utilized.8 They demonstrated that the aminoacylated dinucleotide AppA was able to 
participate in the ligation reaction with T4 RNA ligase and abbreviated tRNA-CCOH to 
produce misacylated tRNAs.8  
There are two widely used methods for the misacylation of tRNAs: chemical and 
enzymatic aminoacylation. Some variations of these methods have been described. In 
addition, chemical aminoacylation in cationic micelles via ultrasonic agitation with 
pdCpA and amino acid, as well as a flexizyme technique have been applied.34-41 Duffy 
and co-workers established a method of aminoacylation via lanthanum(III) and amino 
acid phosphate esters.42 However, none of these methods produce significant amounts of 
bisaminoacylated products.41,43 Meanwhile, chemical aminoacylation has been used to 
attach a variety of amino acids to the 3ʹ′-end of tRNA via pre mono- or bisaminoacylated 
pdCpAs. However, this method is not efficient enough for the production of a variety 
bisaminoacylated species.27 It is hypothesized that the bisaminoacyl derivative is difficult 
to produce due to steric interactions between pdCpA and the amino acid (exemplified in 
Table 2.2). 
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In the chemical route to produce bisaminoacylated pdCpAs, the larger amino acid 
side chains result in lower yields of the bisaminoacylated products. Additionally, the 
synthesis of the precursor pdCpA is rather laborious (scheme 2.5). 
 
 
 
Scheme 2.5. Preparation of mono- and bisaminoacylated tRNACUAs by chemical 
aminoacylation and T4 RNA ligase mediated ligation using pdCpA and tRNA-COH. 
 
However, once the key intermediates, 2.1a-2.5a and 2.1b and 2.5b, required for 
the production of bisaminoacylated tRNAs have been prepared (Figure 2.4, Scheme 2.5), 
they are readily used in T4 RNA ligase-catalyzed condensation reactions with the 
abbreviated suppressor tRNA (tRNA-COH) lacking the 3'-terminal pCpA dinucleotide. 
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Table 2.2. Mono and bisaminoacylation of pdCpA and AMP. 
 
 
 
 We anticipated that as a substrate for aminoacylation, the mononucleotide AMP 
would relieve a portion of the steric restriction due to the absence of the second 
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nucleobase present in pdCpA. We expected that this would result in enhanced 
bisacylation. Hecht and co-workers already demonstrated that aminoacylated AppA can 
act as an aminoacyladenylate donor in a T4 RNA ligation reaction with abbreviated 
tRNA for the production of misacylated tRNAs.8 Therefore, the fidelity of acylation with 
pdCpA and AMP containing several bulky amino acids was examined to determine 
whether this new route would be more effective for obtaining bisactivated tRNAs (Table 
2.2). 
AMP is tolerant to structural modification and retains the ability to form AppA 
derivatives.44 Therefore, we proposed a strategy in which AMP would first be 
aminoacylated, and then converted to the mono- and bisaminoacylated AppA derivatives, 
2.11a-2.15a and 2.11b-2.15b. In the presence of T4 RNA ligase and an abbreviated 
tRNA (tRNA-CCOH) lacking the 3ʹ′-terminal adenosine moiety, this will afford mono- and 
bisaminoacylated tRNAs, A and B (Scheme 2.6)  
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Scheme 2.6. Preparation of mono- and bisaminoacylated tRNACUAs by successive 
aminoacylation of AMP and T4 RNA ligase ligation of aminoacyl-AppA with 
abbreviated tRNA-CCOH. 
 
Transfer RNAs I and II (Schemes 2.5 and 2.6) should be accessible from either 
aminoacylated precursors, pdCpA or AMP. However, efficient aminoacylation with 
amino acids having relatively large side chains may require the utilization of AMP.  
While there are many protecting groups utilized for amines, here it is essential to 
select one amenable to deprotection under conditions compatible with the stability of the 
final aminoacyl-tRNA product. The nitroveratryloxycarbonyl (NVOC) protecting group 
is commonly used as it can be removed by simple UV irradiation.32 As the 4-pentenoyl 
group can be removed under mild conditions (aqueous I2) without disturbing the integrity 
of other functional groups, we decided to employ the latter methodology.25,45 
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Amino acid derivatives were prepared as previously described25 by first protecting 
the amine as the pentenoyl derivative, followed by activation of the acid as the 
cyanomethyl ester. The resulting amino acids (2.11-2.15) were then used to study the 
extent of aminoacylation of both the dinucleotide pdCpA and mononucleotide AMP 
(Table 2.2).  All pdCpA and AMP derivatives were purified by C18 reverse phase HPLC 
using a gradient of 0 → 63% acetonitrile in 50 mM NH4OAc, pH 4.5. In all cases the 
starting material was consumed, however, when aminoacylating pdCpA there was little 
or no production of the bisaminoacylated derivative as seen from the HPLC spectrum.   
The N-pentenoyl protected bisaminoacylated dinucleotide derivatives were ligated to 
abbreviated suppressor tRNACUA transcripts lacking the cytidine and adenosine (pdCpA) 
or adenosine (AppA) moieties normally present at the 3'-terminus of all tRNAs. The 
tRNA transcript was obtained by in vitro run-off transcription of a Fok1-linearized 
plasmid encoding the abbreviated tRNACUA (Fig. 2).20 The ligation reaction was 
catalyzed by T4 RNA ligase.8,11 The formed N-pentenoyl bisacylated tRNAs were 
deprotected by treatment with aqueous iodine as described previously.25,45  
To investigate the extent of aminoacylation of pdCpA and AMP the esterification was 
carried out with a variety of N-protected amino acids bearing bulky side chains, including 
L-phenylalanine, L-1-naphthylalanine, L-2-naphthylalanine, 3-(3,4-dimethoxyphenyl)-L-
alanine, and L-biphenylalanine. 
Initially, pdCpA and AMP were subjected to aminoacylation with phenylalanine to 
determine the extent of aminoacylation with a natural amino acid bearing a large side 
chain. As anticipated, aminoacylation of AMP yielded nearly two-fold more 
bisaminoacylated product than the dinucleotide pdCpA, 67% and 30%, respectively. 
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Consequently, a variety of non-natural amino acids bearing bulky side chains were 
employed for the same esterification reaction and the extent of aminoacylation was 
monitored over a period of three days.  As expected, pdCpA afforded no 
bisaminoacylated product when 3-(3,4-dimethoxyphenyl)-L-alanine, L-1-
naphthylalanine, or L-2-naphthylalanine were used. However, N-protected phenylalanine 
and biphenylalanine esterified both the 2' and 3'-OH groups of the ribose sugar. 
Conversely, the esterification of AMP with the various amino acids was more facile. 
Aminoacylation resulted in greater yields of the bisaminoacylated product as compared to 
the monoacylated adduct, in yields ranging from 55% to 77%.  
 It was substantially easier to obtain the bisacylated derivatives when using AMP 
as compared to pdCpA. While the monoacylation yields of pdCpA are quite high, it is 
presumably more difficult to acylate the second free ribose-OH which results in little 
bisacylated product. Chemical acylation of the sugar is believed to occur at the 2'-OH 
position.46 However, the acylated nucleotide undergoes rapid equilibration to a mixture of 
2' (3')-O-acyladenosine, primarily affording the 3'-O-acylated compound.18 The 
mononucleotide, 5'-AMP, is most likely relieved of the steric interference caused by the 
presence of the cytidine base in pdCpA due to the free rotation about the C5'-O bond of 
adenosine, allowing more facile migration to occur. This suggests that monocleotide 
AMP can better tolerate structural modification than the dinucleotide pdCpA. This 
hypothesis is further supported by work describing the introduction of bulky groups at the 
C-8 position of adenosine without compromising its ability to form 5'→5' diphosphates.44  
 The preparation of AppA was realized by modifying a method published by 
Kanivarioti and co-workers.28 Treatment of aminoacylated AMP with excess 
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imidazolium AMP sodium salt proceeded in very good yields (scheme 2.6). This 
dinucleotide resembles an obligatory intermediate formed in T4 RNA ligase reactions. 
Therefore, no ATP is required for the ligation reaction (Scheme 2.6).47 
Ligation efficiencies of aminoacyl-pdCpAs with tRNA-COHs are easily estimated 
by SDS-PAGE. However, ligation of the AppA derivative and the 75nt tRNA (tRNA-
CCOH) was less obvious. While the product of the ligation reaction contained an 
additional nucleotide and a hydrophobic amino acid, there was no apparent difference in 
mobility between the product and the 75 nt tRNA in SDS-PAGE analysis.  
Verifying the addition of a single nucleotide was rather difficult due to an 
ambiguous result from SDS-PAGE analysis, even though hydrophobic amino acids were 
attached to the tRNAs. 
 The ability of the bisacylated tRNAs to participate in protein synthesis was 
investigated in vitro in an E. coli S30 coupled transcription-translation system in which 
the DHFR gene has a UAG codon at a position corresponding to Val10. Five different 
amino acids were incorporated from two sets of aminoacyl tRNAs (Scheme 2.4). The 
syntheses of full length DHFR in the presence of mono- and bisaminoacylated-tRNAs are 
illustrated in Figures 2.7 and 2.8, respectively. Both mono- and bisaminoacylated-tRNAs 
were shown to effectively suppress the UAG codon, resulting in production of 
comparable amounts of full length DHFR. Some variations were observed while 
employing mono- versus bisaminoacylated-tRNAs for incorporating the same amino 
acid. In the case of L-1-naphthylalanine, L-2-naphthylalanine and L-biphenylalanine, the 
use of bisaminoacylated-tRNAs resulted in the production of approximately 2-3 times 
more DHFR.  
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2.4. Experimental 
2.4.1. General methods and materials 
L-Phenylalanine was purchased from Acros Organics, 3-(3,4-dimethoxyphenyl)-
L-alanine was purchased from Aldrich Chemical Company and all other amino acids 
were purchased from Peptech Corporation. Reagents and solvents for chemical synthesis 
were purchased from Aldrich Chemical Co. or Sigma Chemical Co. and were used 
without further purification. All reactions involving air or moisture-sensitive reagents or 
intermediates were carried out under argon with anhydrous or distilled solvents. 
Analytical TLC was performed using Silicycle silica gel, 60Å F254 plates (0.25 mm), and 
was visualized by UV irradiation (254 nm). Flash chromatography was performed using 
Silicycle silica gel (40-60 mesh). 1H and 13C NMR spectra were obtained using a Varian 
400 MHz NMR spectrometer. Chemical shifts are reported in parts per million (ppm, δ) 
referenced to the residual 1H of the solvent (CDCl3, δ 7.26). 13C NMR spectra were 
referenced to the residual 13C resonance of the solvent (CDCl3, δ 77.16). Splitting 
patterns are designated as follows: s, singlet; d, doublet; dd, doublet of doublets; t, triplet; 
q, quartet; m, multiplet. High-resolution mass spectra were obtained at the Arizona State 
University CLAS High Resolution Mass Spectrometry Facility or Michigan State 
University Mass Spectrometry Facility. HPLC purification was performed with a Waters 
600 pump, Varian ProStar 340 detector, and Grace Econosil C18 column (250 x 10 mm, 5 
µm). The tetra-n-butylammonium (TBA) salt of pdCpA and AMP derivatives were 
prepared using Dowex 50W×8, 200-400 mesh activated in its tetra-n-butylammonium 
form. Gels were visualized and quantified by phosphorimager analysis, which was 
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carried out using an Amersham Biosciences Storm 820 equipped with ImageQuant 
version 5.0 software.  The pixel density of the image was directly related to the amount of 
radioactivity present in the sample by using a calibrated phosphorimager screen. 
 
2.4.2. Synthesis of N-4-pentenoyl cyanomethylester amino acids 
 
4-pentenoyloxy succinimide (2.16)25  
To a solution containing 5.0 mL (49.0 mmol) of pentenoic acid and 5.64 g (49.0 mmol)  
of N-hydroxysuccinimide in 100 mL of CH2Cl2, was added 10.3 g (50.0 mmol) of N,Nʹ′-
dicyclohexylcarbodiimide. After stirring at room temperature for 2 hours, the reaction 
mixture was filtered and the filtrate was concentrated under diminished pressure. 
Crystallization of the crude product from ether−petroleum ether afforded 4-pentenoyloxy 
succinimide (2.16) as colorless needles: yield 7.63 g (79%); Rf 0.43 (1:1 ethyl 
acetate−hexane); mp 45-47 °C (47-48 °C). 
 
N-4-pentenoyl-L-phenylalanine cyanomethyl ester (2.11)25  
To a solution containing 0.50 g (3.02 mmol) of phenylalanine and 0.51g (6.04 mmol) of 
NaHCO3 in 18 mL of 1:1 dioxane–H2O, was added 0.71 g (3.62 mmol) of 2.16. The 
reaction mixture was stirred at room temperature for 16 hours. Eighty mL of 1 N 
O
O
N
O
O
H
N O CN
O
O
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NaHSO4 was then added to the reaction mixture. The aqueous layer was extracted with 
three 100-mL portions of ethyl acetate. The combined organic extract was dried (MgSO4) 
and concentrated under diminished pressure. The crude product was then dissolved in 6 
mL acetonitrile and to the solution was added 2.1 mL (15.1 mmol) of triethylamine and 
0.93 mL (15.1 mmol) of chloroacetonitrile. The reaction mixture was stirred at room 
temperature for 20 hours. Eighty mL of ethyl acetate was then added to the reaction 
mixture. The organic layer was washed with three 75-mL portions of 1 N NaHSO4. The 
organic layer was dried (MgSO4) and concentrated under diminished pressure. The crude 
residue was purified on a silica gel column (45 x 2 cm); elution with 1:1 ethyl 
acetate−hexanes afforded N-pentenoyl-L-phenylalanine cyanomethyl ester (2.11) as a 
colorless solid: yield 0.76 g (88%); mp 52-53 °C (40-41 °C); Rf 0.45 (1:1 ethyl  
acetate−hexane); 1H NMR δ 2.26-2.38 (m, 4H), 3.09-3.19 (m, 2H), 4.68, 4.79 (ABq, 2H, 
J = 15.6 Hz), 4.91-5.06 (m, 3H), 5.72-5.84 (m, 2H), 7.12-7.14 (m, 2H) and 7.29-7.35 (m, 
3H); 13C NMR δ 29.2, 35.3, 37.6, 48.8, 52.8, 105.0, 113.7, 115.9, 127.5, 128.9, 129.1, 
134.9, 136.6, 170.4 and 172.0. 
 
N-4-pentenoyl-L-1-naphthylalanine cyanomethyl ester (2.12) 41 
To a solution containing 0.10 g (0.46 mmol) of L-1-naphthylalanine and 0.80 g (0.92 
mmol) of NaHCO3 in 3 mL of 1:1 dioxane–H2O, was added 0.11 g (0.56 mmol) of 2.16. 
The reaction mixture was stirred at room temperature for 16 hours. Twelve mL of 1 N 
H
N O CN
O
O
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NaHSO4 was then added to the reaction mixture. The aqueous layer was extracted with 
three 15-mL portions of ethyl acetate. The combined organic extract was dried (MgSO4) 
and concentrated under diminished pressure. The crude product was then dissolved in 1 
mL of acetonitrile and to the solution was added 0.32 mL (2.3 mmol) of triethylamine 
and 0.14 mL (2.3 mmol) of chloroacetonitrile. The reaction mixture was stirred at room 
temperature for 20 hours. Twelve mL of ethyl acetate was then added to the reaction 
mixture. The organic layer was washed with three 12-mL portions of 1 N NaHSO4. The 
organic layer was dried (MgSO4) and concentrated under diminished pressure. The crude 
residue was purified on a silica gel column (30 x 2 cm); elution with 1:1 ethyl 
acetate−hexanes afforded N-pentenoyl-L-1-naphthylalanine cyanomethyl ester (2.12) as 
an off-white solid: yield 0.11 g (70%); mp 95-97 °C; Rf 0.45 (1:1 ethyl acetate−hexane); 
1H NMR δ 2.18-2.29 (m, 4H), 3.50-3.60 (m, 2H), 4.55, 4.63 (ABq, 2H, J = 15.7 Hz), 
4.92-5.03 (m, 3H), 5.67-5.74 (m, 1H), 6.02 (d, 1H, J = 6.9 Hz), 7.27 (d, 1H, J = 7.0 Hz), 
7.41 (t, 1H, J = 7.9 Hz), 7.48-7.57 (m, 2H), 7.78 (d, 1H, J = 8.2 Hz), 7.88 (d, 1H, J = 7.9 
Hz) and 8.03 (d, 1H, J = 8.3 Hz); 13C NMR δ 29.1, 34.8, 35.2, 48.8, 52.9, 113.7, 115.8, 
123.1, 125.4, 126.0, 126.6, 127.5, 128.4, 129.0, 131.4, 131.9, 133.9, 136.6, 170.6 and 
172.2; mass spectrum (APCI) m/z 337.1561 (M+H)+ (C20H21N2O3 requires m/z 
337.1552). 
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N-4-pentenoyl-L-2-naphthylalanine cyanomethyl ester (2.13) 41,43 
To a solution containing 57 mg (0.27 mmol) of L-2-naphthylalanine and 0.47 mg (0.54 
mmol) of NaHCO3 in 2 mL of 1:1 dioxane–H2O, was added 63 mg (0.32 mmol) of 2.16. 
The reaction mixture was stirred at room temperature for 16 hours. Two mL of 1 N 
NaHSO4 was then added to the reaction mixture. The aqueous layer was extracted with 
three 2-mL portions of ethyl acetate. The combined organic extract was dried (MgSO4) 
and concentrated under diminished pressure. The crude product was then dissolved in 0.5 
mL acetonitrile and to the solution was added 187 µL (1.3 mmol) of triethylamine and 83 
µL (1.3 mmol) of chloroacetonitrile. The reaction mixture was stirred at room 
temperature for 20 hours. Two mL of ethyl acetate was then added to the reaction 
mixture. The organic layer was washed with three 2-mL portions of 1 N NaHSO4. The 
organic layer was dried (MgSO4) and concentrated under diminished pressure. The crude 
residue was purified on a silica gel column (15 x 2 cm); elution with 1:1 ethyl 
acetate−hexanes afforded N-pentenoyl-L-2-naphthylalanine cyanomethyl ester (2.13) an 
off−white solid: yield 0.058 g (65%); mp 89-90 °C; Rf 0.45 (1:1 ethyl acetate−hexane); 
1H NMR δ 2.25-2.34 (m, 4H), 3.27-3.33 (m, 2H), 4.67, 4.80 (ABq, 2H, J = 16 Hz), 4.78-
5.04 (m, 3H), 5.69-5.79 (m, 1H), 5.91 (d, 1H, J = 7.6 Hz), 7.48-7.50 (m, 2H), 7.60 (s, 
1H) and 7.80-7.84 (m, 3H); 13C NMR δ 29.2, 35.3, 37.7, 48.9, 52.9, 113.8, 115.8, 126.1, 
126.4, 126.9, 127.6, 127.7, 128.0, 128.7, 132.5, 132.6, 133.4, 136.6, 170.4 and 172.2; 
mass spectrum (APCI) m/z 337.1546 (M+H)+ (C20H21N2O3 requires m/z 337.1552). 
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N-4-pentenoyl-3-(3,4-dimethoxyphenyl)-L-alanine cyanomethyl ester (2.14) 
To a solution containing 0.20 g (0.89 mmol) of 3-(3,4-dimethoxyphenyl)-L-alanine and 
0.15 g (1.78 mmol) of NaHCO3 in 5.5 mL of 1:1 dioxane–H2O, was added 0.21 g (1.1 
mmol) of 2.16. The reaction mixture was stirred at room temperature for 16 hours. 
Twenty-four mL of 1 N NaHSO4 was then added to the reaction mixture. The aqueous 
layer was extracted with three 30-mL portions of ethyl acetate. The combined organic 
extract was dried (MgSO4) and concentrated under diminished pressure. The crude 
product was then dissolved in 6 mL acetonitrile and to the solution was added 0.62 mL 
(4.45 mmol) of triethylamine and 0.27 mL (4.45 mmol) of chloroacetonitrile. The 
reaction mixture was stirred at room temperature for 20 hours. Twenty-four mL of ethyl 
acetate was then added to the reaction mixture. The organic layer was then washed with 
three 22-mL portions of 1 N NaHSO4. The organic layer was dried (MgSO4) and 
concentrated under diminished pressure. The crude residue was purified on a silica gel 
column (30 x 2 cm); elution with 1:1 ethyl acetate−hexanes afforded N-pentenoyl-3-(3,4-
dimethoxyphenyl)-L-alanine cyanomethyl ester (2.14) as a colorless solid: yield 0.24 g 
(77%); mp 113-115 °C; Rf 0.50 (1:1 ethyl acetate−hexane); 1H NMR δ 2.20-2.30 (m, 4H), 
2.95-3.06 (m, 2H), 3.78 (s, 6H), 4.62, 4.74 (ABq, 2H, J = 16 Hz), 4.79 (q, 1H, J = 6.4 and 
14 Hz), 4.90-4.99 (m, 2H), 5.65-75 (m, 1H), 6.19 (d, 1H, J = 7.6 Hz), 6.60-6.63 (m, 2H) 
and 6.74 (d, J = 8.1 Hz, 1H); 13C NMR δ 29.0, 35.0, 36.8, 48.6, 52.7, 55.6, 55.7, 111.2, 
H
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112.0, 113.8, 115.4, 121.1, 127.3, 136.4, 148.1, 148.9, 170.3 and 172.0; mass spectrum 
(ESI) m/z 347.1593 (M+H)+ (C18H23N2O5 requires m/z 347.1607). 
 
 
N-4-pentenoyl-L-4,4'-biphenylalanine cyanomethyl ester (2.15) 
To a solution containing 0.21 g (0.92 mmol) of L-4,4'-biphenylalanine and 0.16 g (1.84 
mmol) of NaHCO3 in 5.5 mL of 1:1 dioxane–H2O, was added 0.20 g (1.02 mmol) of 
2.16. The reaction mixture was stirred at room temperature for 16 hours. Twenty-four mL 
of 1 N NaHSO4 was then added to the reaction mixture. The aqueous layer was extracted 
with three 30-mL portions of ethyl acetate. The combined organic extract was dried 
(MgSO4) and concentrated under diminished pressure. The crude product was then 
dissolved in 6 mL acetonitrile and to the solution was added 0.64 mL (4.61 mmol) of 
triethylamine and 0.28 mL (4.61 mmol) of chloroacetonitrile. The reaction mixture was 
stirred at room temperature for 20 hours. Twenty-four mL of ethyl acetate was then 
added to the reaction mixture. The organic layer was then washed with three 23-mL 
portions of 1 N NaHSO4. The organic layer was dried (MgSO4) and concentrated under 
diminished pressure. The crude residue was purified on a silica gel column (30 x 2 cm); 
elution with 1:1 ethyl acetate−hexanes afforded N-pentenoyl-L-phenylalanine 
cyanomethyl ester (2.11) as a colorless solid: yield 0.19 g (56%); mp 129-133 °C; Rf 0.45 
(1:1 ethyl acetate−hexane); 1H NMR δ 2.28-2.40 (m, 4H), 3.14-3.24 (m, 2H), 4.71, 4.82 
H
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(ABq, 2H, J = 15.6 Hz), 4.88-5.06 (m, 3H), 5.73-5.83 (m, 1H), 5.88 (d, 1H, J = 7.6 Hz), 
7.19 (d, 2H, J = 7.2 Hz), 7.33-7.37 (m, 1H), 7.43 (t, 2H, J = 7.8) and 7.55-7.59 (m, 4H); 
13C NMR δ 29.2, 35.4, 37.3, 48.9, 52.8, 113.7, 115.9, 127.0, 127.4, 127.6, 128.8, 129.6, 
133.9, 136.6, 140.4, 140.5, 170.4 and 172.0; mass spectrum (APCI) m/z 363.1723 
(M+H)+ (C22H23N2O3 requires m/z 363.1709). 
 
2.4.3. Synthesis of aminoacyl-pdCpA derivatives 
 
 
Mono-2'(3')-O-(L-phenylalanyl)-pdCpA (2.1a) and Bis-2',3'-O-(L-phenylalanyl)-
pdCpA (2.1b) 
To a conical vial containing 5.0 mg (3.7 µmol) of TBA-pdCpA in freshly distilled DMF 
was added 13 mg (46 µmol) of 2.11 and 4.4 µL (32 µmol) of triethylamine. After stirring  
for three days at room temperature the reaction was purified by reverse phase HPLC 
using a gradient of 1%→65% acetonitrile in 50 mM ammonium acetate buffer (pH = 4.5) 
over 45 minutes to afford monoaminoacylated pdCpA (2.1a): yield 1.9 mg (60%); tR 24  
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minutes; mass spectrum (MALDI) m/z 866.2 (M+H)+ (theoretical m/z 866.6); and 
bisaminoacylated pdCpA (2.1b): yield 1.2 mg (30%); tR 30.6 minutes; mass spectrum 
(ESI) m/z 1095.3405 (M+H)+ (C47H57N10O17P2 requires m/z 1095.3378). 
 
 
Mono-2'(3')-O-(L-2-naphthylalanyl)-pdCpA (2.2a)43  
To a conical vial containing 5.0 mg (3.7 µmol) of TBA-pdCpA in freshly distilled DMF 
was added 16 mg (46 µmol) of 2.12 and 4.4 µL (32 µmol) of triethylamine. After stirring 
for three days at room temperature the reaction was purified by reverse phase HPLC 
using a gradient of 1%→65% acetonitrile in 50 mM ammonium acetate buffer (pH = 4.5) 
over 45 minutes to afford monoaminoacylated pdCpA (2.2a): yield 2.4 mg (70%); tR 24.0 
minutes; mass spectrum (ESI) m/z 916.2410 (M+H)+ (C37H44N9O15P2 requires m/z 
916.2432).  
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Mono-2'(3')-O-(L-2-naphthylalanyl)-pdCpA (2.3a)41,43  
To a conical vial containing 8.3 mg (6.1 µmol) of TBA-pdCpA in freshly distilled DMF 
was added 26 mg (77 µmol) of 2.13 and 7.3 µL (52 µmol) of triethylamine. After stirring 
for three days at room temperature the reaction was purified by reverse phase HPLC 
using a gradient of 1%→65% acetonitrile in 50 mM ammonium acetate buffer (pH = 4.5) 
over 45 minutes to afford monoaminoacylated pdCpA (2.3a): yield 3.6 mg (65%); tR 22.0 
minutes; mass spectrum (ESI) m/z 916.2422 (M+H)+ (C37H44N9O15P2 requires m/z 
916.2432).  
O
O
N
N
NH2
OOPO
O
O N
NN
N
NH2
O
OHO
OPO
O
O
N
H
O
O
O
N
N
NH2
OOPO
O
O N
NN
N
NH2
O
OHO
OPO
O
O
N
H
O
O
O
N
N
NH2
OOPO
O
O N
NN
N
NH2
O
OHO
OPO
O
O
N
H
O
O
O
N
N
NH2
OOPO
O
O N
NN
N
NH2
O
OHO
OPO
O
O
N
H
O
O
O
N
N
NH2
OOPO
O
O N
NN
N
NH2
O
OHO
OPO
O
O
N
H
O
O
O
 45 
 
Mono-2'(3')-O-(3-(3,4-dimethoxyphenyl)-L-alanyl)-pdCpA (2.4a ) 
To a conical vial containing 5.0 mg (3.7 µmol) of TBA-pdCpA in freshly distilled DMF 
was added 16 mg (46 µmol) of 2.11 and 4.4 µL (32 µmol) of triethylamine. After stirring 
for three days at room temperature the reaction was purified by reverse phase HPLC 
using a gradient of 1%→65% acetonitrile in 50 mM ammonium acetate buffer (pH = 4.5) 
over 45 minutes to afford monoaminoacylated pdCpA (2.4a): yield 2.9 mg (84%); tR 28.6 
minutes; mass spectrum (ESI) m/z 926.2451 (M+H)+ (C37H44N9O15P2 requires m/z 
926.2487). 
O
O
N
N
NH2
OOPO
O
O N
NN
N
NH2
O
OHO
OPO
O
O
N
H
O
O
O
N
N
NH2
OOPO
O
O N
NN
N
NH2
O
OHO
OPO
O
O
N
H
O
O
O
N
N
NH2
OOPO
O
O N
NN
N
NH2
O
OHO
OPO
O
O
N
H
O
O
O
N
N
NH2
OOPO
O
O N
NN
N
NH2
O
OHO
OPO
O
O
N
H
O
O
O
N
N
NH2
OOPO
O
O N
NN
N
NH2
O
OHO
OPO
O
O
N
H
O
O
O
 46 
 
Mono-2'(3')-O-(L-4,4'-biphenylalanyl)-pdCpA (2.5a) and Bis-2',3'-O-(L-4,4'-
biphenylalanyl)-pdCpA (2.5b)  
To a conical vial containing 5.0 mg (3.7 µmol) of TBA-pdCpA in freshly distilled DMF 
was added 17 mg (46 µmol) of 2.11 and 4.4 µL (32 µmol) of triethylamine. After stirring 
for three days at room temperature the reaction was purified by reverse phase HPLC 
using a gradient of 1%→65% acetonitrile in 50 mM ammonium acetate buffer (pH = 4.5) 
over 45 minutes to afford monoaminoacylated pdCpA (2.5a): yield 1.7 mg (50%); tR 27.9 
minutes; mass spectrum (ESI) m/z 940.2 (M-H)- (theoretical m/z 940.2); and 
bisaminoacylated pdCpA (2.5b): yield 1.8 mg (40%); tR 37.6 minutes; mass spectrum 
(ESI) m/z 1245.4 (M-H)- (theoretical m/z 1245.4). 
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2.4.4. Synthesis of aminoacyl-AMP derivatives 
 
Mono-2'(3')-O-phenylalanyl-AMP (2.6a) and Bis-2',3'-phenylalanyl-AMP (2.6b)  
To a conical vial containing 6.0 mg (7.2 µmol) TBA-AMP in freshly distilled DMF was 
added 26 mg (91 µmol) of 2.11 and 8.6 µL (62 µmol) of triethylamine. After stirring for 
three days at room temperature the reaction was purified by reverse phase HPLC using a 
gradient of 1%→65% acetonitrile in 50 mM ammonium acetate buffer (pH = 4.5) over 45 
minutes to afford monoaminoacylated AMP (2.6a): yield 1.3 mg (30%); tR 20.6 minutes; 
mass spectrum (ESI) m/z 599.1622 (M+Na)+ (C24H30N6NaO9P requires m/z 599.1631); 
and bisaminoacylated AMP (2.6b): yield 3.9 mg (67%); tR 26.0 minutes; mass spectrum 
(ESI) m/z 806.2880 (M+H)+ (C38H45N7O11P requires m/z 806.2915). 
 
O
N
NN
N
NH2
O
OHO
OPO
O
O
N
H
O
O
N
NN
N
NH2
O
OHO
OPO
O
O
N
H
O
O
N
NN
N
NH2
O
OHO
OPO
O
O
N
H
O
O
N
NN
N
NH2
O
OHO
OPO
O
O
N
H
O
O
N
NN
N
NH2
O
OHO
OPO
O
O
N
H
O
O
O
O
N
N
N
NH2
O
OO
OPO
O
O
N
H
O O
N
H
O
O
N
NN
N
NH2
O
OO
OP
O
O
N
H
O O
N
H
O
O
N
NN
N
NH2
O
OO
OPO
O
O
N
H
O O
N
H
O
O
N
NN
N
NH2
O
OO
OPO
O
O
N
H
O O
N
H
O
O
N
NN
N
NH2
O
OO
OPO
O
O
N
H
O O
N
H
O
O
O
O
O
 48 
 
Mono-2'(3')-O-(L-1-naphthylalanyl)-AMP (2.7a) and Bis-2',3'-O-(L-1-
naphthylalanyl)-AMP (2.7b)41,43 
To a conical vial containing 6.0 mg (7.2 µmol) of TBA-AMP in freshly distilled DMF 
was added 31 mg (91 µmol) of 2.12 and 8.6 µL (62 µmol) of triethylamine. After stirring 
for three days at room temperature the reaction was purified by reverse phase HPLC 
using a gradient of 1%→65% acetonitrile in 50 mM ammonium acetate buffer (pH = 4.5) 
over 45 minutes to afford monoaminoacylated AMP (2.7a): yield 1.5 mg (34%); tR 24.5 
minutes; mass spectrum (ESI) m/z 627.1946 (M+H)+ (C28H32N6O9P requires m/z 
627.1968); and bisaminoacylated AMP (2.7b); yield 3.5 mg (54%); tR 31.0 minutes; mass 
spectrum (ESI) m/z 906.3204 (M+H)+ (C46H49N7O11P requires m/z 906.3228). 
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Mono-2'(3')-O-(L-2-naphthylalany)-AMP (2.8a)41,43 and Bis-2',3'-O-(L-2-
naphthylalanyl)-AMP (2.8b)  
To a conical vial containing 5.0 mg (6.0 µmol) of TBA-AMP in freshly distilled DMF 
was added 26 mg (76 µmol) of 2.13 and 7.2 µL (52 µmol) of triethylamine. After stirring 
for three days at room temperature the reaction was purified by reverse phase HPLC 
using a gradient of 1%→65% acetonitrile in 50 mM ammonium acetate buffer (pH = 4.5) 
over 45 minutes to afford monoaminoacylated AMP (2.8a): yield 1.1 mg (28%); tR 22.5 
minutes; mass spectrum (ESI) m/z 627.1960 (M+H)+ (C28H32N6O9P requires 627.1968); 
and bisaminoacylated AMP (2.8b): yield 3.1 mg (57%); tR 30.8 minutes; mass spectrum 
(ESI) m/z 906.3 (M+H)+ (theoretical m/z 906.3). 
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Mono-2'(3')-O-(3-(3,4-dimethoxyphenylalanyl)-AMP (2.9a) and Bis-2'(3')-O-(3-(3,4-
dimethoxyphenylalanyl)-AMP (2.9b)  
To a conical vial containing 6.0 mg (7.2 µmol) of TBA-AMP in freshly distilled DMF 
was added 32 mg (91 µmol) of 2.14 and 8.6 µL (62 µmol) of triethylamine. After stirring 
for three days at room temperature the reaction was purified by reverse phase HPLC 
using a gradient of 1%→65% acetonitrile in 50 mM ammonium acetate buffer (pH = 4.5) 
over 45 minutes to afford monoaminoacylated AMP (2.9a): yield 1.1 mg (25%); tR 22.1 
minutes; mass spectrum (ESI) m/z 637.2039 (M+H)+ (C26H34N6O11P requires m/z 
637.2023); and bisaminoacylated AMP (2.9b): yield 4.6 mg (67%); tR 29 minutes; mass 
spectrum (ESI) m/z 948.3187 (M+Na)+ (C42H54N7NaO15P requires m/z 948.3157). 
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Mono-2'(3')-O-(L-4,4'-biphenylalanine)-AMP (2.10a) and Bis-2',3'-O-(L-4,4'-
biphenylalanyl)-AMP (2.10b) 
To a conical vial containing 4.0 mg (4.8 µmol) of TBA-AMP in freshly distilled DMF 
was added 22 mg (61 µmol) of 2.12 and 5.7 µL (41 µmol) of triethylamine. After stirring 
for three days at room temperature the reaction was purified by reverse phase HPLC 
using a gradient of 1%→65% acetonitrile in 50 mM ammonium acetate buffer (pH = 4.5) 
over 45 minutes to afford monoaminoacylated AMP (2.10a): yield 0.7 mg (21%); tR 23.8 
minutes; HRMS (ESI) m/z 675.1954 (M+Na)+ (C30H35N6NaO6P requires 675.1944); and 
bisaminoacylated AMP (2.10b): yield 3.6 mg (77%); tR 32.2 minutes; mass spectrum 
(ESI) m/z 980.3327 (M+Na)+ (C50H53N7NaO11P requires m/z 980.3360). 
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2.4.5. Synthesis of aminoacyl-AppA analogues 
 
Mono-2'(3')-O-(L-phenylalanyl)-AppA (2.11a)  
To a conical vial containing 2.2 mg (3.8 µmol) of 2.6a in freshly distilled DMF was 
added 21 mg (50 µmol) of imidazolium AMP sodium salt (I-AMP). After stirring for 
three days at room temperature the reaction was purified by reverse phase HPLC using a 
gradient of 1%→65% acetonitrile in ammonium acetate buffer (pH = 4.5) over 45 
minutes to afford compound 2.11a: yield 3.0 mg (87%); tR 16.0 minutes; mass spectrum 
(ESI) m/z 906.2343 (M+H)+ (C34H42N11O15P2 requires m/z 906.2337). 
 
Bis-2',3'-O-(L-phenylalanyl)-AppA (2.11b) 
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To a conical vial containing 1.6 mg (1.2 µmol) of 2.6b in freshly distilled DMF was 
added 6.8 mg (16 µmol) of I-AMP. After stirring for three days at room temperature the 
reaction was purified by reverse phase HPLC using a gradient of 1%→65% acetonitrile 
in ammonium acetate buffer (pH = 4.5) over 45 minutes to afford compound 2.11b: yield 
1.3 mg (90%); tR 23.4 minutes; mass spectrum (ESI) m/z 1135.3459 (M+H)+ 
(C56H61N12O17P2 requires m/z 1135.3440). 
 
 
 
Mono-2'(3')-O-(L-1-naphthylalanyl)-AppA (2.12a)  
To a conical vial containing 2.0 mg (3.2 µmol) of 2.7a in freshly distilled DMF was 
added 17 mg (42 µmol) of I-AMP. After stirring for three days at room temperature the 
reaction was purified by reverse phase HPLC using a gradient of 1%→65% acetonitrile 
in ammonium acetate buffer (pH = 4.5) over 45 minutes to afford compound 2.12a: yield 
2.9 mg (94%); tR 20.5 minutes; HRMS (ESI) m/z 956.2466 (M+H)+ (C38H44N11O15P2 
requires m/z 956.2494). 
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Bis-2',3'-O-(L-1-naphthylalanyl)-AppA (2.12b)  
To a conical vial containing 3.8 mg (3.8 µmol) of 2.7b in freshly distilled DMF was 
added 23 mg (55 µmol) of I-AMP. After stirring for three days at room temperature the 
reaction was purified by reverse phase HPLC using a gradient of 1%→65% acetonitrile 
in ammonium acetate buffer (pH = 4.5) over 45 minutes to afford compound 2.12a: yield 
4.5 mg (86%); tR 26.0 minutes; mass spectrum (ESI) m/z 1235.3717 (M+H)+ 
(C56H61N12O17P2 requires m/z 1235.3753). 
 
 
Mono-2'(3')-O-(L-2-naphthylalanyl)-AppA (2.13a)  
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To a conical vial containing 1.0 mg (1.6 µmol) of 2.8a in freshly distilled DMF was 
added 8.7 mg (21 µmol) of I-AMP. After stirring for three days at room temperature the 
reaction was purified by reverse phase HPLC using a gradient of 1%→65% acetonitrile 
in ammonium acetate buffer (pH = 4.5) over 45 minutes to afford compound 2.13a: yield 
1.4 mg (93%); tR 18.5 minutes; mass spectrum (ESI) m/z 956.2458 (M+H)+ 
(C38H44N11O15P2 requires m/z 956.2494). 
 
 
 
Bis-2',3'-O-(L-2-naphthylalanyl)-AppA (2.13b)  
To a conical vial containing 3.0 mg (3.3 µmol) of 2.8b in freshly distilled DMF was 
added 18 mg (43 µmol) of I-AMP. After stirring for three days at room temperature the 
reaction was purified by reverse phase HPLC using a gradient of 1%→65% acetonitrile 
in ammonium acetate buffer (pH = 4.5) over 45 minutes to afford compound 2.13b: yield 
3.6 mg (87%); tR 24.6 minutes; mass spectrum (ESI) m/z 1235.3712 (M+H)+ 
(C56H61N12O17P2 requires m/z 1235.3753). 
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Mono-2'(3')-O-(3-(3,4-dimethoxyphenyalanyl)-AppA (2.14a)  
To a conical vial containing 1.8 mg (2.8 µmol) of 2.9a in freshly distilled DMF was 
added 15 mg (37 µmol) of I-AMP. After stirring for three days at room temperature the 
reaction was purified by reverse phase HPLC using a gradient of 1%→65% acetonitrile 
in ammonium acetate buffer (pH = 4.5) over 45 minutes to afford compound 2.14a: yield 
2.3 mg (85%); tR 19.0 minutes; mass spectrum (ESI) m/z 966.2539 (M+H)+ 
(C36H46N11O17P2 requires m/z 966.2549). 
 
 
Bis-2',3'-O-(3-(3,4-dimethoxyphenylalanyl)-AppA (2.14b) 
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To a conical vial containing 4.0 mg (4.3 µmol) of 2.7b in freshly distilled DMF was 
added 24 mg (56 µmol) of I-AMP. After stirring for three days at room temperature the 
reaction was purified by reverse phase HPLC using a gradient of 1%→65% acetonitrile 
in ammonium acetate buffer (pH = 4.5) over 45 minutes to afford compound 2.14b: yield 
4.4 mg (81%); tR 22.4 minutes; mass spectrum (ESI) m/z 1255.3921 (M+H)+ 
(C52H65N12O21P2 requires m/z 1255.3862). 
 
 
Mono-2'(3')-O-(L-4,4'-biphenylalanyl)-AppA (2.15a)  
To a conical vial containing 1.2 mg (1.8 µmol) of 2.10a in freshly distilled DMF was 
added 10 mg (24 µmol) of I-AMP. After stirring for three days at room temperature the 
reaction was purified by reverse phase HPLC using a gradient of 1%→65% acetonitrile 
in ammonium acetate buffer (pH = 4.5) over 45 minutes to afford compound 2.15a: yield 
1.3 mg (81%); tR 20.7 minutes; mass spectrum (ESI) m/z 982.2695 (M+H)+ 
(C40H46N11O15P2 requires m/z 982.2650). 
O
N
NN
N
NH2
O
OHO
OP
O
O
N
H
O
O
N
N N
N
NH2
O
O P
O
O
OH OH
O
N
NN
N
NH2
O
OHO
OPO
O
O
N
H
O
O
N
N N
N
NH2
O
O P
O
OH OH
O
N
N N
N
NH2
O
O P
O
OH OH
O
N
N N
N
NH2
O
O P
O
OH OH
O
N
N N
N
NH2
O
O P
O
OH OH
O
N
NN
N
NH2
O
OHO
OPO
O
O
N
H
O
O
N
NN
N
NH2
O
OHO
OPO
O
O
N
H
O
O
N
NN
N
NH2
O
OHO
OPO
O
O
N
H
O
O
O
 58 
 
Bis-2',3'-O-(L-4,4'-biphenylalanyl)-AppA (2.15b)  
To a conical vial containing 2.3 mg (2.4 µmol) of 2.10b in freshly distilled DMF was 
added 13 mg (31 µmol) of I-AMP. After stirring for three days at room temperature the 
reaction was purified by reverse phase HPLC using a gradient of 1%→65% acetonitrile 
in ammonium acetate buffer (pH = 4.5) over 45 minutes to afford compound 2.15b: yield 
2.3 mg (79%); tR 25.6 minutes; mass spectrum (ESI) m/z 1287.4072 (M+H)+ 
(C56H61N12O17P2 requires m/z 1287.4066). 
 
2.4.6. Preparation of mono and bis-aminoacyl-tRNAs 
Mono and bis-aminoacyl-tRNAs were prepared by a T4 RNA ligase-mediated ligation of 
the protected, chemically synthesized pdCpA and AppA derivatives (2.1-2.5 and 2.11-
2.15, respectively), with the abbreviated suppressor tRNA-COH. The ligation reaction was 
carried out in 100 µL (total volume) of 100 mM HEPES, pH 7.5, containing 0.5 mM 
ATP, 15 mM MgCl2, 100 µg of suppressor tRNA-COH, 2.0 A260 unit of N-pentenoyl-
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protected mono- or bis-aminoacyl-pdCpA derivatives (5- to 10-fold molar excess), 15% 
DMSO and 200 units of T4 RNA ligase.  After incubation at 37 ºC for 30 minutes, the 
reactions were quenched by the addition of 10 µL of 3 M NaOAc, pH 5.2, followed by 
300 µL of ethanol.  The reaction mixtures were incubated at -20 ºC for 30 minutes and 
centrifuged at 14,000 x g (30 minutes, 4 ºC).  The supernatants were carefully decanted.  
The pellets were washed with 50 µL of 70% ethanol and dissolved in 50 µL of H2O.  The 
efficiencies of ligation when utilizing pdCpA were estimated by gel electrophoresis, pH 
5.2 (100 V, 2 hours). To a solution containing 100 µg of aminoacyl-tRNA in 50 µL of 
water was added 12 µL of 25 mM I2 (6.3 mg iodine was dissolved in 1 mL of 1:1 H2O–
THF).  The reaction mixtures were incubated for 10 minutes at 25 ºC, then 6 µL of 3 M 
NaOAc was added.  The tRNAs were precipitated by the addition of 200 µL of ethanol, 
then centrifuged at 14,000 x g (30 minutes, 4 oC) and the supernatants were carefully 
decanted.  The pellets were washed with 50 µL of 70% ethanol and then dissolved in 30 
µL of water. 
 
2.4.7. In vitro translation of DHFR 
In vitro translation was performed using a bacterial S-30 extract from E. coli strain 
BL21(DE3). The reaction mixture (20 µL total volume) containing 2 µg of pETDH10 
plasmid, containing mutant DHFR gene (TAG codon in position corresponding to 
Val10), 8 µL of premix (35 mM Tris-acetate, pH 7.0, 190 mM potassium glutamate, 30 
mM ammonium acetate, 2.0 mM dithiothreitol, 11 mM magnesium acetate, 20 mM 
phosphoenolpyruvate, 0.8 mg/mL of E.coli tRNA, 0.8 mM isopropyl β-D-
 60 
thiogalactopyranoside, 20 mM ATP and GTP, 5 mM CTP and UTP, 4 mM cAMP), 250 
µM of each of the 20 amino acids, 5µCi of [35S]-methionine, 10 µg/µL rifampicin, 30 µL 
of bacterial S-30 extract from E.coli strain BL21(DE3) and 0.6 µg of aminoacyl-
tRNACUA was incubated at 37 ºC for 45 minutes. As a control, the in vitro translation was 
also carried out in the presence of mono-aminoacyl-tRNACUA.  Aliquots from in vitro 
translation mixtures were analyzed by SDS-PAGE following by quantification of the 
radioactive bands by phosphorimager analysis. Suppression efficiency was calculated as 
the percentage of the protein produced via nonsense codon suppression relative to the 
production of wild-type protein. 
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CHAPTER 3 
SYNTHESIS OF CAGED DMT-THIOTHREONYL-DHFR 
 ANALOGUES 
 
3.1. Introduction 
Many biologically significant peptides and peptidomimetics contain non-
proteinogenic amino acids with functionalized side chains, and significant effort has been 
expended developing synthetic routes for the preparation of such compounds.48-52 In fact, 
a common way to realize post-translational protein modifications is via the use of 
reagents that react with specific amino acid side chains. The introduction of a limited 
number of non-natural amino acids into predetermined positions in proteins can be an 
effective method to target specific sites for modification. In particular, a non-natural 
amino acid having a single thiol functional group can be introduced into a target protein 
and subsequently transformed by reagents that react with S atoms, such as maleimide 
esters.  
The thiothreonines prepared in this study were incorporated into a modified 
DHFR protein lacking cysteine residues (csDHFR), facilitating site-specific protein 
modification at introduced thiothreonine and allo-thiothreonine residues via treatment 
with a thiol specific fluorophore, 7-diethylamino-3-(4'-maleimidylphenyl)-4-
methylcoumarin (CPM). The fluorescent prosthetic group was introduced at the level of 
pdCpA, suppressor tRNA, or protein to define the optimal methodology for introducing 
specific functionalities into proteins. 
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 As part of our ongoing efforts to enable the synthesis of modified proteins 
containing mechanistically interesting non-proteinogenic amino acids,22,23,53-63 we 
focused on the synthesis of β-methylcysteine (thiothreonine). Thus, the syntheses of L-
thiothreonine and L-allo-thiothreonine (Figure 3.1) were undertaken utilizing a novel 
strategy.  
 
 
Figure 3.1. Structures of the β-methylcysteine (thiothreonine) stereoisomers synthesized. 
  
3.2. Results 
 Dr. Nour Eddine Fahmi performed a substantial number of the chemical 
transformations for the preparation of the following molecules, and I extend the sincerest 
gratitude for his assistance with this project. The synthesis of protected L-thiothreonines 
(3.4a and 3.4b, Scheme 3.1) commenced with the preparation of the NVOC derivative of 
either L-allo- or L-thiothreonine, by treatment of the respective amino acid with 6-
nitroveratryl chloroformate (NVOCCl), the latter of which was prepared according to the 
procedure described by Katritzky et al.64 Thus, L-allo-threonine or L-threonine was 
dissolved in a 1:1 mixture of dioxane and water in the presence of sodium bicarbonate, to 
which NVOCCl was added. Upon stirring for 17 hours at room temperature, NVOC-
protected threonine derivatives, 3.1a and 3.1b, were obtained following work-up in 60 
OH
OSH
NH2
OH
OSH
NH2
L-thiothreonine L-allo-thiothreonine
(2R,3R)-β-methylcysteine (2R,3S)-β-methylcysteine
 63 
and 85% yields, respectively.  3.1a or 3.1b was then solubilized in dichloromethane and 
treated with triethylamine and HBTU and left to stir at room temperature under argon. 
Following stirring for 20 hours, extractive work-up followed by silica gel column 
chromatography gave the desired lactones 3.2a and 3.2b in 60 and 65% yield, 
respectively. Treatment of 3.2a and 3.2b with potassium thioacetate in DMF at room 
temperature for 23 hours afforded thioacetates 3.3a and 3.3b, regio- and 
stereospecifically in 85 and 82% yields, respectively, after purification. Following 
opening of the lactone the acetate group was hydrolyzed using lithium hydroxide and the 
resulting free thiol was treated with 4,4'-dimethoxytrityl chloride in the presence of 
triethylamine to give the orthogonally protected L-thiothreonine and L-allo-thiothreonine 
3.4a and 3.4b in 51 and 84% yields, respectively.  
 
 
Scheme 3.1. Synthesis of N,S-orthogonally protected L-thiothreonine and L-allo-
thiothreonine derivatives 3.4a and 3.4b. 
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 Conversion of 3.4a and 3.4b to their corresponding cyanomethyl ester derivatives 
was accomplished by treatment with chloroacetonitrile in dry acetonitrile in the presence 
of triethylamine to afford compounds 3.5a and 3.5b in 67 and 85% yields, respectively. 
Treatment of the cyanomethyl esters with the tris-(tetrabutylammonium) salt of pdCpA in 
anhydrous DMF afforded the corresponding aminoacylated pdCpAs 3.6a and 3.6b in 21 
and 47% yields, respectively (Scheme 3.2).  
 
 
Scheme 3.2. Synthesis of N,S-orthogonally protected L-thiothreonine and L-allo-
thiothreonine derivatives of pdCpA 3.6a and 3.6b. 
 
Removal of the DMT group at the pdCpA level was performed on protected L-
allo-thiothreonyl pdCpA ester 3.14 using silver nitrate in aqueous acetonitrile, followed 
by treatment with dithiothreitol to afford the free thiol (Scheme 3.4). The dinucleotide 
was labeled on the sulfur atom with a coumarin fluorophore [7-diethylamino-3-(4′-
maleimidophenyl)-4-methylcoumarin] in acetonitrile−water, and the fluorescent 
dinucleotide 3.16 was obtained in 64% yield after purification by HPLC (Scheme 3.3 and 
Figure 3.2). 
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Scheme 3.3. Synthesis of thiothreonyl- and allo-thiothreonyl-tRNACCUAs. 
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Figure 3.2. HPLC analysis of pdCpA derivatives of allo-thiothreonine. 
 
Following treatment of 3.6b with silver nitrate, two new peaks at 22.9 and 23.3 minutes 
(corresponding to the free thiol) were observed, as well as the disappearance of the peaks 
at 33.1 and 33.7, indicating the reaction was complete and quantitative. Moreover, 
coupling of the dye, mediated by maleimide chemistry, was very efficient, proceeding 
quantitatively as seen by the disappearance of thepeakes at 33.1 and 33.7 minutes and the 
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appearance of a new peak at 35.6 minutes. 
 Importantly, the technology developed herein allows for the introduction of the 
conjugated adduct (the dye coupled thiol) at various stages leading to the production of 
protein, as well as at the protein level itself. 
 
3.3. Discussion 
 We reported the preparation of L-thiothreonine and L-allo-thiothreonine 
stereoisomers utilizing a novel ring opening reaction involving threonine-derived 
lactones. Lactone ring opening, using LiSH and NaSH as nucleophiles, afforded a β-
isothiouronium salt, a plausible precursor to a β-methylcysteine derivative. This strategy 
was therefore applied for the synthesis of NVOC protected β-methylcysteine using 
potassium thioacetate as the nucleophile for ring opening of the β-lactone at the β-carbon 
atom (Scheme 3.1).  
 L-allo-threonine and L-threonine were employed as starting materials and were 
treated initially with NVOCCl, leading to N-protection and affording compounds 3.1a  
and b, followed by treatment with HBTU to produce β-lactone derivatives 3.2a and 3.2b. 
Opening of the β-lactone ring was facilitated by potassium thioacetate to afford the 
thioacetate derivatives 3.3a and 3.3b. Transformation of the thiol protecting group by 
hydrolysis of the acetate with lithium hydroxide, followed by treatment the resulting free 
thiol with 4,4′-dimethoxytrityl chloride, was achieved in high yield. The conversion of 
protected compounds 3.4a and 3.4b to the corresponding cyanomethyl esters (3.5a and 
3.5b) was achieved by treatment with chloroacetonitrile in dry acetonitrile in the presence 
of triethylamine.  
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The treatment of the active esters 3.5a and 3.5b with the tris-
(tetrabutylammonium) salt of pdCpA in anhydrous DMF gave the corresponding 
aminoacylated pdCpAs 3.6a and 3.6b, respectively. Removal of the DMT group at the 
pdCpA level was performed on protected L-allo-thiothreonyl pdCpA ester 3.6b using 
silver nitrate in aqueous acetonitrile, followed by treatment with dithiothreitol, DTT 
(Scheme 3.3 and Figure 3.2).  
The dinucleotide was labeled on the sulfur atom with a coumarin fluorophore [7-
diethylamino-3-(4′-maleimidophenyl)-4-methylcoumarin] in acetonitrile−water and the 
fluorescent dinucleotide 3.8 was obtained following HPLC purification. Suppressor 
tRNACUAs activated with either L-thiothreonine or allo-L-thiothreonine were prepared as 
outlined in Scheme 3.3. The aminoacylated pdCpAs were ligated to an abbreviated 
suppressor tRNACUA transcript (tRNACUA-COH, lacking the terminal cytidine and 
adenosine moieties present at the 3ʹ′-terminus of all tRNAs) via a T4 RNA ligase 
mediated ligation reaction to obtain the N and S-protected thiothreonyl-tRNACUAs. The 
ligation efficiencies were evaluated via denaturing PAGE analysis as shown in Figure 
3.3.65  
 
 
 69 
 
Figure 3.3. Ligation of thiothreonyl-pdCpA derivatives to tRNACUA-COH. Lane 1, 74 nt 
abbreviated suppressor tRNACUA; Lane 2, 76 nt thiothreonyl-tRNACUA; Lane 3, 76 nt 
allo-thiothreonyl-tRNACUA. 
 
 The N-protected aminoacylated tRNAs were then irradiated with UV light at 0 °C 
for 5 minutes to afford the activated tRNAs having amino acids with free α-amines. 
Evaluation of the deprotection efficiency of the DMT group was investigated prior to 
photolysis. A portion of the fully protected tRNAs were subjected to treatment with silver 
nitrate, followed by treatment with dithiothreitol, affording thiothreonyl-tRNACUAs 
having free sulfhydryl groups. Removal of the DMT group was verified via coupling with 
the coumarin fluorophore and visualized by irradiating with 365 nm wavelength light 
(Figure 3.4). 
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Figure 3.4. Coupling of the NVOC-protected thiothreonyl-tRNA analogues with CPM 
after DMT group removal. 
 
 Allo-thiothreonyl-tRNACUA derivatized with the same fluorophore was also 
prepared by a T4 RNA ligase-mediated coupling of dinucleotide 14 with tRNA-COH 
(Scheme 3.4). Following irradiation with UV light to remove the NVOC protecting 
group, the CPM-derivatized allo-thiothreonyl-tRNACUA was employed in a protein 
synthesis system, as described below. 
The ability of thiothreonyl-tRNACUAs to participate in protein synthesis was 
evaluated in a bacterial cell free protein synthesis system. A plasmid encoding modified 
E. coli DHFR where the Cys85 and Cys152 codons were replaced with serine codons was 
used. This modified DHFR has been found to retain nearly full enzymatic activity (Figure 
3.5). This work was performed by Dr. Shengxi Chen.  
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!
 71 
 
Figure 3.5. Enzymatic activity of csDHFR compared to that of wild-type DHFR. 
 
Additionally, a stop codon (TAG) was incorporated into the plasmid at DHFR 
position 10 to facilitate incorporation of the thiothreonine derivatives from the 
misacylated suppressor tRNAs (Scheme 3.4).  
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Scheme 3.4. Strategy employed for incorporation of thiothreonines into csDHFR and 
coupling with CPM. 
 
 Both L-thiothreonyl-tRNACUA and L-allo-thiothreonyl-tRNACUA were found to 
participate in protein synthesis, affording DHFRs with 43% and 45% suppression 
efficiencies, respectively, relative to the amount of csDHFR produced from the 
corresponding mRNA lacking any stop codon (Figure 3.6). The DMT-protected 
thiothreonine and allo-thiothreonine were incorporated in yields of 28% and 26%, 
respectively. In comparison, the incorporation of the fluorescently labeled allo-
thiothreonine from CPM-derivatized allo-thiothreonyl-tRNACUA (prepared by ligation of 
3.8 and tRNA-COH) proceeded in low (~5%) yield. In replicate experiments, the 
incorporation of CPM-allo-thiothreonine into csDHFR ranged from 2–8%.  
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Figure 3.6. In vitro incorporation of thiothreonine derivatives into csDHFR at position 
10. 
 
 All of the proteins were purified successively on Ni-NTA and DEAE-Sepharose 
columns, as illustrated for the thiothreonine-containing DHFR in Figure 3.7. These 
experiments were performed by Dr. Shengxi Chen. 
 
 
Figure 3.7. Purification of thiothreonyl-DHFR by successive chromatography on Ni-
NTA and DEAE Sepharose columns. 
 
 
Figure. In vitro synthesis of DHFR utilizing monoacylated tRNACUAs to suppress 
a UAG codon at position 10 of DHFR mRNA. Lane 1, wild-type mRNA; Lane 2, 
no tRNACUA; lane 3, L-phenylalanyl-tRNACUA; lane 4, L-thiothreonyl-tRNACUA; lane 
5, L-allo-thiothreonyl-tRNACUA; lane 6, L-(S)-DMT-thiothreonyl-tRNACUA; lane 7, 
L-allo-(S)-DMT-thiothreonyl -tRNACUA  
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 Coupling of the purified proteins containing malemide fluorophore labeled 
(position 10) thiothreonine and allo-thiothreonine was visualized by irradiating with 365 
nm wavelength light (Figure 3.8). These experiments were performed by Dr. Shengxi 
Chen. As is clear from the figure, the fluorophore was readily introduced into the nascent 
csDHFRs containing thiothreonine and allo-thiothreonine. As anticipated, the csDHFRs 
elaborated with DMT-protected thiothreonine and allo-thiothreonine did not react 
detectably with the coumarin fluorophore. 
 
 
Figure 3.8.  Coupling of thiothreonyl-csDHFR analogues with CPM. All of the protein 
samples were purified chromatographically prior to treatment with the fluorophore. 
 
 In the present study, we used a DMT group to protect the thiol groups of L-
thiothreonine and L-allo-thiothreonine. The DMT group can be removed at the pdCpA 
and tRNA levels, and both the DMT-protected and unprotected thiothreonyl- and allo-
thiothreonyl-tRNACUAs were used to incorporate the thiolated amino acids at  
position 10 of csDHFR. The nascent csDHFRs containing unprotected thiothreonine and  
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allo-thiothreonine readily reacted with CPM, affording protein that was fluorescently 
labeled at a single position. However, the DMT group could not be removed from the 
thiothreonines at the protein level due to protein precipitation under the conditions used 
for deprotection. The free thiol groups of thiothreonine and allo-thiothreonine could be 
modified with the fluorophore CPM at the pdCpA, tRNA and protein levels. The CPM-
protected allo-thiothreonyl-tRNACUA, however, proved to be a poor substrate in the 
peptidyltransferase reaction, such that the preferred method for elaborating the 
fluorescent protein was by direct derivatization of the initially formed csDHFR 
containing a free SH group in the amino acid at position 10. 
 
3.4. Experimental 
 
3.4.1. General materials and methods 
 
Reagents and solvents for chemical synthesis were purchased from Aldrich Chemical Co. 
or Sigma Chemical Co. and used without further purification. Ni-NTA agarose was 
obtained from Qiagen Inc. (Valencia, CA). DNA oligonucleotides were ordered from 
Integrated DNA Technologies (Coralville, IA). DEAE-Sepharose, ammonium persulfate, 
acrylamide, N, N´-methylene-bis-acrylamide, acetic acid, potassium glutamate, 
ammonium acetate, dithiothreitol, magnesium acetate, phospho(enol)pyruvate, 
Escherichia coli tRNA, isopropyl β-D-thiogalactopyranoside (IPTG), ATP, GTP, CTP, 
UTP, cAMP, amino acids, rifampicin, formamide and 7-diethylamino-3-(4′-
maleimidophenyl)-4-methylcoumarin (CPM) were obtained from Sigma-Aldrich (St. 
Louis, MO). Tris and SDS were obtained from Bio-Rad Laboratories (Hercules, CA). 
[35S]-methionine (1000 Ci/mmol, 10 µCi/µL) was purchased from PerkinElmer Inc. 
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(Boston, MA). Protease inhibitor (complete, EDTA-free) was obtained from Boehringer 
Mannheim Corp. (Indianapolis, IN). T4 RNA ligase and T4 polynucleotide kinase were 
purchased from New England Biolabs Inc. (Ipswich, MA). Phosphorimaging analysis 
was performed using an Amersham Biosciences Storm 820 equipped with ImageQuant 
version 5.2 software from Molecular Dynamics. UV spectral measurements were 
performed using a Perkin-Elmer Lamdba 20 UV/vis spectrometer. Fluorescence was 
monitored at 365 nm. The mutant csDHFR analogues modified at position 10 with 
thiothreonine were prepared using the general strategy shown in Scheme 5.22,23,31,53-63,66   
 
3.4.2. Preparation of thiothreonyl-pdCpA derivatives 
 
 
S-(4,4′-Dimethoxytrityl)-N-(6-nitroveratryloxycarbonyl)-L-thiothreonyl pdCpA 
ester (3.6a) 
To a conical vial containing 16.0 mg (22.4 µmol) S-(4,4′-dimethoxytrityl)-N-(6-
nitroveratryloxycarbonyl)-L-thiothreonine cyanomethyl ester (3.5a) was added a solution 
containing 5.8 mg (4.3 µmol) of the tris-(tetrabutylammonium) salt of pdCpA in 90 µL of 
anhydrous DMF followed by 10 µL of triethylamine. The reaction mixture was stirred at 
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room temperature under argon atmosphere for 24 hours. A 5-µL aliquot of the reaction 
mixture was diluted with 55 µL of 1:1 CH3CN/50 mM NH4OAc at pH 4.5 and was 
analyzed by HPLC on a C18 reverse phase column (250 × 10 mm). The column was 
washed with 1 → 65% CH3CN in 50 mM NH4OAc at pH 4.5 over a period of 45 minutes 
at a flow rate of 3.5 mL/minute (monitored at 260 nm). The remaining reaction mixture 
was diluted to a total volume of 0.6 mL with CH3CN and purified using the same C18 
reverse-phase column. S-(4,4′-Dimethoxytrityl)-N-(6-nitroveratryloxycarbonyl)-L-
thiothreonyl pdCpA ester (3.6a) (retention time 33.8 and 34.4 minutes) was recovered 
from the appropriate fractions as a colorless solid by lyophilization: yield 1.2 mg (21%); 
mass spectrum (ESI), m/z 1295.3136 (M+H)+ (C54H61N10O22P2S requires m/z 1295.3158). 
 
 
S-(4,4'-Dimethoxytrityl)-N-(6-nitroveratryloxycarbonyl)-L-allo-thiothreonyl pdCpA 
ester (3.6b) 
To a conical vial containing 16.0 mg (22.4 µmol) of S-(4,4'-dimethoxytrityl)-N-(6-
nitroveratryloxycarbonyl)-L-allo-thiothreonine cyanomethyl ester (3.5b) was added a 
solution of 5.8 mg (4.3 µmol) of the tris-(tetrabutylammonium) salt of pdCpA in 90 µL 
of anhydrous DMF, followed by 10 µL of triethylamine. The reaction mixture was stirred 
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at room temperature under argon atmosphere for 24 hours. A 5-µL aliquot of the reaction 
mixture was diluted with 55 µL of 1:1 CH3CN/50 mM NH4OAc at pH 4.5 and was 
analyzed by HPLC on a C18 reverse phase column (250 × 10 mm). The column was 
washed with 1 → 65% CH3CN in 50 mM NH4OAc at pH 4.5 over a period of 45 minutes 
at a flow rate of 3.5 mL/minute (monitoring at 260 nm). The remaining reaction mixture 
was diluted to a total volume of 0.6 mL with CH3CN and purified using the same C18 
reverse phase column. S-(4,4'-dimethoxytrityl)-N-(6-nitroveratryloxycarbonyl)-L-allo-
thiothreonyl pdCpA ester (3.6b) (retention time 34.0 and 34.5 minutes) was recovered 
from the appropriate fractions as a colorless solid by lyophilization: yield 2.6 mg (47%); 
mass spectrum (ESI), m/z 1295.3203 (M+H)+ (C54H61N10O22P2S requires 1295.3158). 
 
 
N-(6-nitroveratryloxycarbonyl)-L-allo-thiothreonyl pdCpA ester (3.7) 
To a solution containing 1.6 mg (1.23 µmol) of S-(4,4'-dimethoxytrityl)-N-(6-
nitroveratryloxycarbonyl)-L-allo-thiothreonyl pdCpA ester (3.6b) in 0.60 mL of 3:1 
acetonitrile/water (v/v) was added a solution containing 3.13 mg (18.5 µmol) of AgNO3 
in 40 µL of water. The reaction mixture was stirred at room temperature for 1 hour, then 
9.5 mg (61.6 µmol) of dithiothreitol in 50 µL of water was added and stirring was 
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continued for 90 minutes. The mixture was centrifuged at 15,000 × g at 4 °C for 5 
minutes and the supernatant was collected and purified by HPLC on a C18 reverse phase 
column (250 × 10 mm). The column was washed with 1 → 65% CH3CN in 50 mM 
NH4OAc at pH 4.5 over a period of 45 min at a flow rate of 3.5 mL/min (monitoring at 
260 nm). N-(6-Nitroveratryloxycarbonyl)-L-allo-thiothreonyl pdCpA ester (3.7) 
(retention time 22.9 and 23.3 min) was recovered from the appropriate fractions as a 
colorless solid by lyophilization and was used immediately in the next step: yield 1.0 mg 
(82%); mass spectrum (MALDI), m/z 993.4 (M+H)+ (theoretical m/z 993.2). 
 
 
S-[7-Diethylamino-3-(4'-maleimidophenyl)-4-methylcoumarin]-N-(6-
nitroveratryloxycarbonyl)-L-allo-thiothreonyl pdCpA ester (3.8) 
To a solution containing 1.0 mg (1.0 µmol) of N-(6-nitroveratryloxycarbonyl)-L-allo-
thiothreonyl pdCpA ester (3.7) in 375 µL of 2:1 acetonitrile/water (v/v) was added 0.8 
mg (2.0 µmol) of 7-diethylamino-3-(4'-maleimidophenyl)-4-methylcoumarin in 75 µL of 
acetonitrile. The mixture was stirred at room temperature for 3 hours, then purified by 
HPLC on a C18 reverse phase column (250 × 10 mm). The column was washed with 1 → 
65% CH3CN in 50 mM NH4OAc at pH 4.5 over a period of 45 minutes at a flow rate of 
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3.5 mL/minute (monitored at 260 nm). S-[7-Diethylamino-3-(4'-maleimidophenyl)-4-
methylcoumarin]-N-(6-nitroveratryloxycarbonyl)-L-allo-thiothreonyl pdCpA ester (3.8) 
(retention time of 34-35 min) was recovered from the appropriate fractions as a yellow 
solid by lyophilization: yield 0.9 mg (64%); mass spectrum (MALDI), m/z 1395.6 
(M+H)+ (C57H65N12O24P2S requires 1395.3). 
 
3.4.3. Ligation of suppressor tRNACUA-COH with thiothreonine analogues and 
deprotection of DMT and NVOC groups 
Activation of suppressor tRNACUA was carried out in 100 µL (total volume) of 100 mM 
Hepes buffer, pH 7.5, containing 2.0 mM ATP, 15 mM MgCl2, 100 µg of suppressor 
tRNA-COH, 2.0 A260 units of protected aminoacyl-pdCpA (5-10 fold molar excess), 15% 
DMSO and 200 units of T4 RNA ligase. After incubation at 37 oC for 1 hour, the reaction 
was quenched by the addition of 10 µL of 3 M NaOAc, pH 6.3, followed by 300 µL of 
ethanol. The reaction mixture was incubated at –20 oC for 30 minutes, then centrifuged at 
15,000 × g at 4 oC for 30 minutes. The supernatant was carefully decanted and the tRNA 
pellet was washed with 100 µL of 70% ethanol and dissolved in 100 µL of RNase free 
H2O. The efficiency of ligation was estimated by 8% denaturing PAGE (pH 5.2).65 The 
DMT protecting group of N-(6-nitroveratryloxycarbonyl)-thiothreonyl-tRNA or N-(6-
nitroveratryloxycarbonyl)-allo-thiothreonyl-tRNA was removed by treatment with 
50 mM AgNO3 at room temperature for 30 minutes, followed by treatment with 60 mM 
DTT at room temperature for 30 minutes.67 The reaction mixture was centrifuged at 
15,000 × g at 4 oC for 10 minutes, and then the supernatant was carefully decanted. The 
precipitated pellet was washed with 100 µL of 0.3 M NaOAc, pH 6.3. The combined 
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aqueous supernatant was treated with 600 µL of ethanol to precipitate the tRNA. The 
tRNA pellet was washed with 100 µL of 70% ethanol and then dissolved in 30 µL of 
RNase free H2O. The NVOC-protected aminoacyl-tRNA was cooled to 2 oC and 
irradiated with a 500 W mercury-xenon lamp for 5 minutes.32,45 After irradiation, the 
deblocked aminoacylated suppressor tRNAs were using in vitro suppression experiments 
without further purification.  
 Also prepared were samples of the thiothreonyl- and allo-thiothreonyl-tRNAs in 
which the DMT group was not removed prior to photolysis of the NVOC protecting 
group. 
 
3.4.4. Coupling of NVOC-thiothreonyl-tRNA analogues with CPM 
The NVOC-thiothreonyl-tRNA coupling was carried out in 50 µL (total volume) of 
100 mM NaOAc, pH 6.3, containing 90 µg of thiothreonyl-tRNA analogue and 1 mM of 
CPM. The reaction was incubated at room temperature for 1 hour and was quenched by 
the addition of 3 µL of 3 M NaOAc, pH 6.3, followed by 150 µL of ethanol. The reaction 
mixture was incubated at –20 oC for 30 minutes, then centrifuged at 15,000 × g at 4 oC 
for 30 minutes. The supernatant was carefully decanted and the tRNA pellet was washed 
with 50 µL of 70% ethanol and dissolved in 30 µL of RNase free H2O. The fluorescence 
was monitored at ~ 470 nm following irradiation at 365 nm. 
 
3.4.5. Ligation of suppressor tRNA-COH with CPM-allo-thiothreonyl-pdCpA and 
deprotection of NVOC groups  
Suppressor tRNA aminoacylation was carried out in 100 mL (total volume) of 100 mM 
 82 
Hepes buffer, pH 7.5, containing 2.0 mM ATP, 15 mM MgCl2, 100 µg of suppressor 
tRNA-COH, 2.0 A260 units of NVOC-protected CPM-allo-thiothreonyl-pdCpA, 15% 
DMSO and 200 units of T4 RNA ligase. After incubation at 37 oC for 1 hour, the reaction 
was quenched by the addition of 10 µL of 3 M NaOAc, pH 5.2, followed by 300 µL of 
ethanol. The reaction mixture was incubated at –20 oC for 30 minutes, then centrifuged at 
15,000 × g at 4 oC for 30 minutes. The supernatant was carefully decanted and the tRNA 
pellet was washed with 100 µL of 70% ethanol and dissolved in 30 µL of RNase free 
H2O. The NVOC-protected CPM-allo-thiothreonyl-tRNA was cooled to 2 oC and 
irradiated with a 500 W mercury-xenon lamp for 5 minutes.  
 
3.4.6. In vitro translation of csDHFR analogues 
The wild-type csDHFR plasmid was obtained by site-directed mutation as described as 
previously, using wild-type DHFR plasmid as the template (prepared by Dr. Chen).33 The 
DNA primer for the mutation at position 85 is  
5'-GATGAAGCCATCGCGGCGTCTGGTGACGTACCAGAAATC-3'; the primer for 
the mutation at position 152 is  
5'-CAGAACTCTCACAGCTATAGCTTTGAGATTCTGGAGC-3'. The mutant csDHFR 
(TAG at position 10) was obtained by the same site-directed mutation using the wild-type 
csDHFR plasmid as the template and a sequence of  
5'-GTCTGATTGCGGCGTTAGCGTAGGATCGCGTTATCGGCATG-3' as the primer.  
The in vitro expression mixture (300 µL total volume) contained 30 µg of mutant DHFR 
(TAG at position 10) plasmid DNA, 120 µL of premix (35 mM Tris-acetate, pH 7.0, 190 
mM potassium glutamate, 30 mM ammonium acetate, 2.0 mM dithiothreitol, 11 µM 
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maganesium acetate, 20 mM phospho(enol)pyruvate, 0.8 mg/mL of E. coli tRNA, 
0.8 mM IPTG, 20 mM ATP and GTP, 5 mM CTP and UTP and 4 mM cAMP), 100 mM 
of each of the 20 amino acids, 30 mCi of [35S]-L-methionine, 10 µg/µL rifampicin, 90 µg 
of deprotected misacylated tRNACUA and 90 µL of S-30 extract from E. coli strain 
BL21(DE3). The reaction mixture was incubated at 37 oC for 45 minutes. Plasmid DNA 
containing the gene for wild-type csDHFR was used as the positive control, and an 
abbreviated tRNA (tRNA-COH) lacking any amino acid was used as the negative control. 
An aliquot containing 2 µL of reaction mixture was removed, treated with 2 µL of 
loading buffer and heated at 90 oC for 2 minutes. This was analyzed by 15% SDS-PAGE 
at 100 V for 2 hour.  
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CHAPTER 4 
SYNTHESIS OF CAGED DHFRS  
WITH PROTECTED PHOSPHOROTYROSINES 
 
4.1. Introduction  
 Protein phosphorylation is a universal, post-translational mechanism for 
activation or deactivation of proteins and for the regulation of cell signaling events, 
differentiation, metabolism, neuronal communication and signal transduction of many 
life forms.68-71 Two amino acids are generally implicated in protein phosphorylation 
events, namely serine and threonine.72 It has been shown, however, that tyrosine, 
histidine, aspartate and glutamate are also targets of phosphorylation.72,73 Additionally, 
radiolabeling studies have suggested that nearly 30% of eukaryotic proteins are subject to 
phosphorylation.72 The signals that initiate and terminate phosphorylation are regulated 
by kinases and phosphoprotein phosphatases, respectively74,75, and abnormal 
phosphorylation events have been implicated in many diseases.76-78 The importance of 
kinases in cell signaling is consistent with their relative abundance in the eukaryotic 
family; they constitute nearly 2% of the entire genome. This realization has resulted in 
their broad study.71,79,80 The discovery that glycogen is activated by means of 
phosphorylation prompted intensive research in an attempt to understand the conversion 
between the following two states: the active glucose-1-phosphate (phosphorylase a) and 
the inactive glycogen (phosphorylase b).81,82 It was formulated that a protein kinase, 
phosphorylase kinase (PhK), phosphorylated two Ser residues, thereby inducing a 
conformational shift that rendered the protein active. In fact, one of the requirements for 
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activity is phosphorylation of PhK, an event that is carried out by another phosphorylase 
kinase, protein kinase A (PKA). Accordingly, the idea of protein phosphorylation as a 
regulatory process was soon realized.68,83-85 Protein phosphorylation has been shown to 
support a number of physiological processes, and defects in these signaling pathways 
have been linked to pathogenic mechanisms such as cancer and other human diseases. 
Moreover, protein-tyrosine kinases (PTKs) have been shown to function in growth 
control; phosphorylation of tyrosine residues is a major mechanism of transmembrane 
signaling.86-88 Biochemical analysis of protein phosphorylation events and their effects 
are typically demonstrated through site-directed mutagenesis and replacement of known, 
post-translationally modified Ser, Thr or Tyr residues with Ala for Ser/Thr and Phe for 
Tyr.89  
Chemical approaches for examining protein phosphorylation and phosphorylated 
protein function include the use of photolabile caged analogs of amino acids and the 
introduction of amino acid derivatives.  
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Figure 4.1. Phosphoregulation of proteins. Kinases and phosphatases add or remove 
phosphate groups in amino acids, respectively. Alternatively, a caged phosphate can be 
removed by irradiation to reveal the phosphate. 
 
Caged compounds are typically photolabile molecules or probes that functionally 
encapsulate biomolecules in an inactive form by masking the functional groups required 
for activity. Irradiation of the biologically masked species removes the photolabile 
molecule and releases the active species, the phosphate, into the system. There are several 
attributes required for a protecting group to be effective for caging: (1) it doesn’t function 
as an agonist or an antagonist, (2) following irradiation the molecule is released rapidly 
and in high yield, (3) the byproducts of release should be inert, and (4) the photolytic 
conversion should be accessible under physiological conditions.90 The predominant 
structural motif for biological investigations is derived from the O-nitrobenzyl 
functionality. The O-nitrobenzyl group is inert within living cells, has a relatively good 
quantum yield of uncaging, is excited with nearly visible light which will not cause 
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radiative damage to cells and releases byproducts that are water soluble.91 
Caged, phosphorylated amino acids are ideal probes for studying phosphorylated 
protein interactions and cell signaling pathways as they offer both spatial (the site of the 
protein) and temporal control over targeted effector molecules. We, therefore, sought to 
develop a variety of caged phosphorylated tyrosine derivatives for the purpose of 
aminoacylating tRNAs and evaluating their incorporation into proteins. Interestingly, 
ribosomal acceptance of the free phosphotyrosine, the mono-ester (singly protected), and 
the di-ester (doubly protected) varied drastically. Similar observations have been 
previously documented, with a variety of charged amino acids slowing the ribosomal 
synthetic machinery. In vitro expression systems utilizing amber stop codons are also 
biased against charged amino acids. Specifically, a variety of aspartic acids residues were 
utilized for protein synthesis and only an allyl protected aspartic acid was able to 
participate in protein synthesis most efficiently.66 While there have been several studies 
on the preparation of caged phosphoproteins, there are limited reports that illustrate the 
ability of the ribosome to incorporate a variety of phosphorylated amino acids in varying 
states of caging, i.e. the free phosphate versus the singly and the doubly caged adducts, 
compounds 4.1, 4.2 and 4.3, respectively.  
 
 
Figure 4.2. Synthesized phosphorylated tyrosine derivatives. 
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Ribosomal acceptance of bulky non-natural amino acids tends to diminish with 
increasing amino acid side chain size. Therefore, the steric bulk resulting from masking 
the phosphate charge could potentially result in poor incorporation of the amino acid. 
A more widely accepted and applied method involves the use of phosphate-
specific antibodies. Phosphate-specific antibodies are capable of binding and detecting 
phosphorylation-induced conformational changes in proteins; however, it’s still unclear 
whether the antibodies recognize the phosphorylated amino acid or the altered protein 
conformation.  
Two-dimensional gels are considered the easiest method for detection,92,93 as the 
electrophoretic mobility should be altered due to the addition of a phosphate group. 
However, two-dimensional gels typically require a large amount of sample handling. 
Consequently, it is difficult to reproduce results and the method suffers from a smaller 
dynamic range than other methods. Mass spectrometry is a powerful tool when more 
comprehensive assessments of protein phosphorylation are required. However, it too has 
its limitations; for a thorough review see Mann et al.94 In order to verify the 
identity/incorporation of the protected p-Tyr into proteins, we selected mass spectrometry 
for our identification method. 
 
4.2. Results  
The synthesis of phosphorotyrosyl-tRNA was initiated by the preparation of N-
pentenoyl phosphorotyrosine, via treatment of phosphorotyrosine 4.4 with pentenoic acid 
succinimide ester to afford 4.5 (Scheme 4.1). The N-protected amino acid was then 
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treated with chloroacetonitrile and triethylamine in an attempt to activate the C-terminus 
as the cyanomethyl ester derivative. However, when attempting to activate the acid we 
observed multiple additions via MALDI-TOF MS analysis, putatively leading to 
compounds 4.6a-4.6e as outlined in scheme 4.1. 
 
 
Scheme 4.1. Synthesis of protected phosphotyrosines activated as cyanomethyl esters. 
 
Activating the carboxylic acid in the presence of a free phosphate group has the 
potential of resulting in a complex mixture of products and was, therefore, revised. We 
instead initiated the synthesis from free tyrosine, 4.7. Again, the amine was protected as 
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the pentenoyl derivative by treatment with pentenoic acid succinimide ester, followed by 
activation as the cyanomethyl ester via chloroacetonitrile, to afford compound 4.8 in 48% 
yield. Treatment of 4.8 with phosphitylating agent 4.9 in the presence of tetrazole, 
followed by oxidation with tert-butylhydroperoxide afforded compound 4.11 in 60% 
yield over two steps. Similarly, compound 4.12 was prepared in 36% yield by 
phosphorylation of 4.8 with phosphitylating agent 4.10 in the presence of tetrazole, 
followed by subsequent oxidation with tert-butylhydroperoxide and deprotection with 
TFA (Schemes 4.2 and 4.3).53,95  
 
 
Scheme 4.2. Route employed for the synthesis of doubly caged phosphorylated tryrosine. 
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Scheme 4.3. Route employed for the synthesis of singly caged phosphorylated tryrosine. 
 
Aminoacylation of the dinucleotide pdCpA with compounds 4.11 and 4.12, in 
DMF in the presence of triethylamine  (Schemes 4.4 and 4.5), proceeded quite slowly and 
resulted in challenging HPLC purification. Surprisingly, sonicating the reaction under 
similar conditions afforded compounds 4.13 and 4.15 in better yields, 62 and 58%, 
respectively, and shorter reaction times, ranging from 1-12 hours.  
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Scheme 4.4. Route employed for the synthesis di-nitrobenzylphosphotyrosyl-pdCpA and 
phosphotyrosyl-pdCpA. 
 
Moreover, following aminoacylation of pdCpA with compound 4.11, irradation of 
4.13 afforded the free phosphate derivative, compound 4.14, in quantitative yield.  
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Scheme 4.5. Synthesis of mono-nitrobenzylphosphotyrosyl-pdCpA. 
 
 The following biological experiments were carried out by Dr. Larissa Dedkova 
and Rumit Maini: preparation of abbreviated tRNACUA, ligation of abbreviated tRNA and 
aminoacylated pdCpAs, in vitro protein translation of DHFR and proteolytic digestion of 
DHFR with trypsin. The preparation of abbreviated suppressor tRNAs was performed by 
transcription of plasmid pYRNA8,22 followed by digestion with FokI to afford tRNA-
COH.11 The elaborated, abbreviated tRNA was then purified on a DEAE-Sepharose 
column by eluting with a sodium chloride gradient. 
 Aminoacylation of the abbreviated tRNACUAs was carried out by a T4 RNA ligase 
mediated reaction with the N-protected, chemically synthesized pdCpA derivatives to 
afford the activated suppressor tRNAs (Scheme 4.6 and Figure 4.3) 
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Scheme 4.6. Preparation of protected phosphotyrosyl-tRNACUAs by T4 RNA ligase  
mediated ligation of amionoacyl-pdCpA and abbreviated tRNA-CCOH. 
 
 
Figure 4.3. Ligation of phosphorotyrosyl-pdCpA derivatives to tRNACUA-COH. (analyzed 
on an acidic 8% polyacrylamide-7M urea gel)65. Lane 1, nonacylated tRNACUA;  Lane 2, 
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NVOC-tyrosyl-pdCpA;53 Lane 3, phosphorotyrosyl-pdCpA (4.15); Lane 4, mono-
nitrobenzyl-phosphorotyrosyl-pdCpA (4.16); Lane 5, dinitrobenzyl-phosphorotyrosyl-
pdCpA (4.14). 
 
The resulting ligation reactions were analyzed by polyacrylamide gel 
electrophoresis under acidic conditions.65 Gel shift analysis of the ligation reaction as 
shown by bands with retarded migration (lanes 2-5), compared to the abbreviated tRNA 
(lane 1), suggests nearly quantitative ligation efficiencies. 
The ability of the aminoacylated suppressor tRNACUAs to participate in protein 
synthesis was estimated by the synthesis of full length DHFR encoded by two plasmids, 
pETDH10 and pETDH49, that contained TAG codons at the positions corresponding to 
Val10 and Ser49, respectively. The in vitro experiments were performed using bacterial 
S-30 extract from E. coli strain BL21 (DE3). The reaction mixtures were incubated at 37 
°C for 45 minutes. Aliquots from the in vitro translation mixtures employing pETDH10 
and pETDH49 were analyzed via SDS-PAGE and the results are shown in Figures 4.4 
and 4.5, respectively.  
 
 
Figure 4.4. In vitro synthesis of DHFR utilizing monoaminoacylated tRNACUAs to 
suppress a UAG codon at position 10 of DHFR mRNA. Lane 1, tyrosyl-tRNACUA 
1        2         3         4         5         6        7         8         9 
 
                         50      0.4      100      89       31       11        5        11      16      suppression 
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(prepared from NVOC-tyrosyl-pdCpA);53 Lane 2, nonacylated tRNACUA ; Lane 3, 
phenylalanyl-tRNACUA; Lane 4, phenylalanyl-tRNACUA, prepared from phenylalanyl-
pdCpA, irradiated with UV light prior to ligation;  Lane 5, phosphorotyrosyl-tRNACUA  
(both hydroxyl groups protected with nitrobenzyl groups); Lane 6, phosphorotyrosyl-
tRNACUA  (prepared from phosphorotyrosyl-pdCpA, treated with UV light following 
ligation); Lane 7, phosphorotyrosyl-tRNACUA  (prepared from phosphorotyrosyl-pdCpA, 
treated with UV light prior ligation); Lane 8, phosphorothreonyl-tRNACUA (one 
phosphate –OH group is protected with a nitrobenzyl group). 
  
 
 
Figure 4.5. In vitro synthesis of DHFR utilizing di-nitrobenzyl-phosphorotyrosyl-
tRNACUAs to suppress a UAG codon at position 49 of DHFR mRNA. Lane 1, wild-type 
mRNA; Lanes 2-4, modified mRNA containing a UAG codon at position 49; Lane 2, 
threonyl-tRNACUA, Lane 3, no tRNACUA, Lane 4, di-nitrobenzyl-phosphotyrosyl-
tRNACUA 
 
Analyses to confirm the introduction of phosphorotyrosine were carried out in 
two ways. First, we visualized proteolytic digestion of DHFR utilizing endoproteinase 
GluC.  
!
1 2 3 4
100 37 1 10 % suppression
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Briefly, radiolabeled DHFR samples were prepared by in vitro translation 
reactions in the presence of 35S-methionine and purified by successive chromatographic 
purifications on Ni-NTA and DEAE-Sepharose columns. The purified DHFR samples 
were then transferred to 50 µL of 50 mM Tris-HCl, pH 8.0, containing 0.5 mM Glu-Glu, 
by the use of a YM-10 ultrafiltration device. Digestion of the protein was carried out in 
20 µL reactions; 20 ng of each DHFR sample (~ 107 cpm, as verified by liquid 
scintillation counting) was mixed with 2 µg of GluC endoproteinase and incubated at 25 
ºC for 16 hours. Following incubation, the samples were quenched by the addition of 2 
µL of 1.1 % formic acid and the final samples (5 -10 µL) were analyzed by 20% Tris-
tricine polyacryalamide gel electrophoresis27, followed by phosphorimager analysis, as 
shown in Figure 4.6. 
 
Figure 4.6. GluC endoproteinase digestion of Ser49dinitrobenzyl-phosphorotyrosyl 
DHFR with varying concentrations of GluC endoproteinase. Lane M, molecular weight 
marker; Lane 1, non-digested DHFR; Lane 2, digested sample of DHFR having di-
nitrobenzyl-phosphorotryosine in position 49 and treated with 0.5 µg/mL GluC 
26 kDa
14 kDa
3.5 kDa
2.2 kDa
 M 1 2 3 4
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endoproteinase; Lane 3, digested sample of DHFR having di-nitrobenzyl-
phosphorotryosine in position 49 and treated with 1 µg/mL GluC endoproteinase; Lane 4, 
digested sample of DHFR having di-nitrobenzyl-phosphorotryosine in position 49 and 
treated with 2 µg/mL GluC endoproteinase. 
One aliquot of the digested protein was then irradiated to uncage the peptide of 
interest, while another aliquot was left untreated. Both aliquots were then analyzed via 
reverse phase-HPLC by co-injection with the synthetically prepared peptide standard. 
Fractions were collected from both HPLC purifications and analyzed by liquid 
scintillation counting. It should be noted that an authentic peptide, 
GMGIVRD(phosphoroT)ALAAILSIM (Figure 4.7) was synthesized via solid phase 
peptide synthesis (SPPS) as a standard and was co-injected (Figure 4.8) with all samples. 
Initial attempts to synthesize the peptide utilizing an automated system were 
unsuccessful; the reason for that still remains unclear.  
 
 
Figure 4.7. Structure of peptide synthesized by SPPS. 
 
We reasoned that introducing the fully protected phosphorylated tyrosine 
hindered the coupling event, due to the bulkiness of the side chain. Therefore, the peptide 
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was synthesized by an automated system and removed from the capillary prior to the 
introduction of the phosphorylated tyrosine, GMGIVRD. Following removal of the resin 
from the capillary, the coupling of Fmoc-phosphorotyrosine was carried out on the resin 
in a sealed tube and was allowed to react overnight under normal solid phase coupling 
conditions. Quantitative Fmoc cleavage indicated the coupling reaction was complete and 
the resin was placed back into the capillary; the remainder of the peptide was synthesized 
on the automated system. All in vitro synthesized proteins were purified by NiNTA 
columns, desalted, and concentrated prior to further analysis. 
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Figure 4.8. HPLC profiles of the authentic peptide before (blue) and after (red) 
irradiation, visualized by absorbance at 260 nm (bottom) or by radioactivity (upper). 
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A mobility shift from the apex of each peak is quite apparent and was expected. 
Uncaging of the peptide liberates the free phosphate, resulting in a slightly more polar 
peptide. Notably, not all of the peptide was uncaged (deprotected), as can be seen by the 
results shown in Figure 4.8. Moreover, it should be further noted that the completely 
uncaged peptide does not absorb at 260 nm. The red trace, corresponding to the irradiated 
peptide, can be described as follows: the peak at 39 minutes can be putatively identified 
as the bis-nitrobenzylphospho peptide and the peak at 38 minutes as the mono-
nitrobenzylphospho peptide. Analysis of the in vitro synthesized DHFR did not afford 
enough product to be identified by UV detection. Characterization was therefore 
performed by liquid scintillation counting of fractions, as shown by the lower panel in 
Figure 4.8.  
The sensitivity of the scintillation analysis offers additional information about the 
products after irradiation of the peptides. The appearance of a new peak at 36.4 minutes 
(red), is apparent following irradiation. This peak can potentially be identified as the 
product resulting from the loss of two nitrobenzyl groups, a fact that would not be 
detectable by UV.  
Further confirmation of ribosomal incorporation of the modified amino acids, as 
directed by the UAG codon in the mRNA, was illustrated by MALDI-TOF MS 
characterization. MALDI-TOF MS analysis had to be performed on the protein 
containing a point mutation at position 49 because the His tag at the N-terminus of DHFR 
(used for purification) diminishes the response of N-terminal peptides in MALDI-TOF 
MS.  
DHFR samples for MALDI-TOF MS analysis were prepared from non-
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radiolabeled reaction mixtures employing pETDH49 plasmid with a TAG codon at 
position 49 of the DHFR gene. Following expression, the reaction mixture was subjected 
to a 12% SDS-polyacrylamide gel and subsequently stained with Coomassie R-250 for 
DHFR identification. The gel was de-stained until the background was clear. The DHFR 
band was identified, extracted from the gel, and proteolytically digested by trypsin.  
A second mutant, Ser49Phe, prepared from misacylated tRNA was prepared in a 
similar fashion for comparative MALDI-TOF MS analysis. The resulting peptide 
fragments were analyzed via MALDI-TOF MS by preparing solutions of the digested 
protein on a dihydroxybenzoic acid (DHB) matrix. The spectrometric data for the wild-
type, Ser49Phe and Ser49dinitrobenzylphosphoTyr DHFRs are shown below in Figures 
4.9, 4.10 and 4.11, respectively. 
 
Figure 4.9. MALDI-TOF MS of tryptic fragments of wild-type DHFR. 
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Figure 4.10. MALDI-TOF MS of tryptic fragments of Ser49Phe DHFR. 
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Figure 4.11. MALDI-TOF MS of tryptic fragments of Ser49dinitrobenzyl-
phosphotyrosyl DHFR. 
 
Comparative analysis of the peptide fragments from the two mutants and wild-
type DHFR further verified the incorporation of the desired amino acid at the 
predetermined position. For Ser49Phe DHFR, a tryptic fragment containing 
phenylalanine at the fifth position of the peptide is expected to have a molecular mass of 
1566. Accordingly, as seen in figure 4.10, there was a molecular ion peak observed at m/z 
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1567 that is not present in the tryptic digest of wild-type DHFR. Moreover, the same 
molecular ion peaks corresponding to the remaining six tryptic digests containing amino 
acids 13-106 of DHFR could be seen in both wild-type and Ser49Phe DHFR. 
Analogously, Ser49dinitrobenzylphosphoTyr DHFR showed molecular ion peaks 
corresponding to m/z 1792 and 1661,which supports the incorporation of the di-
nitrobenzylphosphotyrosine resulting from the loss of one and both nitrobenzyls (Figure 
4.11). A summary of the tryptic digest patterns are outlined in Table 4.1. 
 
Table 4.1. 
MALDI-TOF MS analysis of tryptic digests of wild-type and modified DHFR samples.  
 
 
 
Position 
 
 
Peptide sequence 
 
MALDI-TOF MS analysis, molecular mass, Da 
 
 
Wild-type 
 
Modified 
DHFR 1 
 
Modified 
DHFR 2 
Est MS Est MS Est MS 
 
34-44 NTLNKPVIMGR 1242 1242.8 1242 1242.6  1242 1242.8 
45-57 HTWESIGRPLPGR 1506 1505.8 1566 1566.3 *1797 1793.2 
59-71 NIILSSQPGTDDR 1415 1415.8 1415 1415.6  1415 1415.8 
72-76 VTWVK 632 632.5 632 634.3 632 632.4 
Modified DHFR 1: phenylalanine in position 49; modified DHFR 2: phosphorotyrosine 
analogue 4.3 in position 49. Position 49 is indicated in red. *The molecular mass 
resulting from the loss of one nitrobenzyl protecting group on the phosphate. 
 
Table 4.1 presents the anticipated molecular mass and observed molecular ion 
peaks resulting from proteolytic digestion of wild-type and modified DHFRs 1 and 2, 
containing Phe or 4.3, respectively, with trypsin. The wild-type peptide and mutant 
containing Phe at position 49 showed ion peaks at 1506 (anticipated molecular mass 
1506) and 1566 (anticipated molecular mass 1566), respectively, which is in good 
agreement with the expected molecular masses. The molecular ion peak observed for  
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modified DHFR 2 did not correspond to the anticipated molecular mass. The observed 
ion for modified DHFR 2, however, is in close agreement with the peptide resulting from 
loss of one nitrobenzyl protecting group on the phosphate. Similar occurrences were 
observed when preparing compounds 4.1-4.3. 
 
4.3. Discussion  
 The synthetic route leading to the three phosphorylated tyrosines (4.1-4.3, Figure 
4.3), as well as the aminoacylated dinucleotides (4.14-4.16, Scheme 4.4 and 4.5) for the 
preparation of phosphotyrosyl-tRNACUA variants (Scheme 4.6) was very efficient because 
they all share a common intermediate, compound 4.7. Phosphorylation of 4.8 with 
phosphitiling agents 4.9 or 4.10, afforded caged phosphotyrosine dervatives as the mono- 
or diesters, 4.11 and 4.12, bearing one or two nitrobenzyl groups, respectively. Yields 
and reaction times for phosphorylation of the phenolic alcohol are in good agreement 
with previously published reports.95 Initially, oxidation of the phosphite was performed 
with iodine. However, purification proved to be rather difficult and was simplified by 
employing tert-butylhydroperoxide. Aminoacylation of pdCpA with 4.11 and 4.12 
afforded aminoacylated pdpCpAs 4.14 and 4.16 and irradiation of 4.14 afforded the third 
aminoacylated pdCpA 4.15, containing a free phosphate. The efficiency of the 
aminoacylation reaction was greatly enhanced by sonicating the reaction mixture. 
Interestingly, phosphorotyrosyl-pdCpA, mono-nitrobenzyl-phosphorotyrosyl-pdCpA and 
di-nitrobenzyl-phosphorotyrosyl-pdCpA were ligated to abbreviated tRNACUAs very 
efficiently, in yields greater than 80% (Figure 4.4). The extent to which the 
phosphorylated tyrosine derivatives were protected on the phosphate group appears to 
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have a direct effect on the ability of the tRNA to suppress the nonsense codon in in vitro 
protein synthesis (Figure 4.5). The ability of the di-nitrobenzyl-phosphotyrosyl-tRNACUA 
to participate in DHFR synthesis in our in vitro system via suppression of a UAG codon 
at position 10 of the corresponding mRNA was reasonably efficient, ~31% relative to the 
suppression efficiency of Phe-tRNACUA. Mono-nitrobenzyl-phosphorotyrosyl-tRNACUA 
and phosphorotyrosyl-tRNACUA were able to suppress the UAG codon with efficiencies 
of only 11 and 5%, respectively, as compared to phenylalanyl-tRNACUA (Figure 4.5). It 
should be noted that phenylalanyl-tRNACUA typically exhibits suppression efficiencies in 
the range of 60-90%. The inability of charged aminoacylated tRNACUAs to efficiently 
participate as suppressor tRNAs in in vitro protein synthesis has already been reported. 
For example, it was shown that aspartyl-tRNAs suppress nonsense codons much more 
efficiently when the amino acid side chain is protected. This effect is also demonstrated 
by the phosphoryltyrosyl-tRNAs prepared from the pdCpA derivatives discussed here. 
Phosphorylated tyrosyl-tRNAs bearing two protecting groups on the phosphate were able 
to suppress a UAG codon more efficiently than those containing one or no protecting 
groups. 
To provide evidence of the successful incorporation of the phosphorylated 
tyrosines described here into DHFR, two independent experiments were performed: co-
elution on HPLC and identification of peptide fragments from digestion of in vitro 
synthesized proteins as compared to a synthetically prepared standard; and MALDI-TOF 
MS characterization. The synthetic standard was prepared by modified solid phase 
peptide synthesis. After synthesis, the peptide was cleaved from the resin and purified by 
RP-HPLC. Irradiation of the synthetically prepared peptide standard afforded a 
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substantial decrease in the amount of peptide bearing two nitrobenzyl groups, and an 
increase in the mono-nitrobenzylated peptide, as evidenced in Figure 4.8. Irradiation 
resulting in a peptide that lost both nitrobenzyl groups would not be detectable at 260 nm, 
and liquid scintillation counting was required to identify the peptide prepared in the in 
vitro system, as can be seen in Figure 4.8. 
 Further verification of the incorporation of phosphorotyrosine is evident by the 
mass spectrometric data. Due to the relatively small difference in molecular weight 
between wild type DHFR and Ser49phosphoTyr DHFR, analysis of the whole protein is 
not advisable. To circumvent this problem, the protein was proteolytically digested by 
trypsin and the resulting fragments were analyzed by mass spectrometry. Initial attempts 
to digest the protein with GluC endoproteinase proved inadequate, as the enzyme is less 
efficient than trypsin and the molecular ion peaks corresponding to the peptide fragments 
could not be observed by MALDI-TOF MS. Therefore, following purification by Ni-
NTA, DEAE-Sephadex, and SDS-polyacrylamide gel electrophoresis, the proteins were 
treated with trypsin according to a published “in-gel” protocol.96 The resulting peptide 
fragments were subjected to MALDI-TOF MS analysis, (Figures 4.9, 4.10 and 4.11), 
performed by Dr. Larissa Dedkova and Rumit Maini. Two samples (wild-type DHFR and 
Ser49Phe DHFR) were used as controls for MALDI-TOF MS analysis of the mutant 
DHFR containing di-nitrobenzyl-phosphorotyrosine (the only phosphorotyrosyl 
employed for MALDI-TOF MS analysis due to expression yields). Comparative analysis 
of the peptide fragments from the two mutant and wild-type DHFRs further verified the 
incorporation of the desired amino acid at the predetermined position. Regarding 
Ser49Phe DHFR, a tryptic fragment containing phenylalanine at the fifth position of the 
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peptide is expected to have a molecular mass of 1566. Accordingly, as seen in Figure 
4.10, there was a molecular ion peak observed at m/z 1567 that was not present in the 
tryptic digest of wild-type DHFR. Moreover, the same molecular ion peaks 
corresponding to the other tryptic peptide fragments containing amino acids 13-106 of 
DHFR were present for both wild-type and Ser49Phe DHFR. Analogously, 
Ser49dinitrobenzylphosphoTyr DHFR showed molecular ion peaks corresponding to m/z 
1792 and 1661 (Figure 4.11) which is in support of the successful incorporation of the di-
nitrobenzylphosphorotyrosine resulting from the loss of one or both nitrobenzyl groups. 
 Accordingly, incorporation of deprotected phosphorylated tyrosines should be 
amenable to the same type of analysis. However, the poor efficiency with which they 
participate in ribosomally mediated protein synthesis precludes our ability to characterize 
the products. Recently, Hecht and co-workers described ribosomal selection for the 
synthesis of DHFR containing β-amino acids, with suppression efficiencies up to 18%.30 
If this technology were developed to incorporate negatively charged amino acids it would 
be possible to pursue the incorporation of a variety of phosphorylated amino acids. 
 
4.4. Experimental  
4.4.1. General methods and materials 
L-Tyrosine was purchased from Alfa Aesar. All other reagents and solvents for chemical 
synthesis were purchased from Sigma Aldrich Co. and used without further purification. 
All reactions involving air- or moisture-sensitive reagents or intermediates were 
performed under argon. Flash chromatography was performed using Silicycle silica gel 
(40–60 mesh). Analytical TLC was performed using EM silica gel 60 F254 plates 
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(0.25 mm) and was visualized by UV irradiation (254 nm). 1H and 13C NMR spectra were 
obtained using a 400 MHz Varian NMR instrument. Chemical shifts are reported in parts 
per million (ppm, δ) referenced to the residual 1H resonance of the solvent (CDCl3, δ 
7.26; CD3OD, δ 3.31, DMSO-d6, δ 2.50). 13C NMR spectra were referenced to the 
residual 13C resonance of the solvent (CDCl3, δ 77.16; CD3OD, δ 49.00, DMSO-d6, δ 
39.52). Splitting patterns are designated as follows: s, singlet; d, doublet; dd, doublet of 
doublets; t, triplet; q, quartet; quint, quintet; m, multiplet; br, broad. HPLC purification 
was performed with a Waters 600 pump coupled with a Varian ProStar 340 detector and 
a Grace Econosil C18 column (250 × 10 mm, 5 µm). The tetra-n-butylammonium (TBA) 
salts of pdCpA were prepared using Dowex 50WX8, 200-400 mesh activated in its TBA 
form.  High-resolution mass spectra were obtained at the Arizona State University CLAS 
High Resolution Mass Spectrometry Laboratory or at the Michigan State University Mass 
Spectrometry Facility. Ni-NTA agarose was obtained from Qiagen Inc. (Valencia, CA). 
DNA oligonucleotides were purchased from Integrated DNA Technologies (Coralville, 
IA). DEAE-Sepharose, ammonium persulfate, acrylamide, N, N´-methylene-bis-
acrylamide, acetic acid, potassium glutamate, ammonium acetate, dithiothreitol, 
magnesium acetate, phospho(enol)pyruvate, Escherichia coli tRNA, isopropyl β-D-
thiogalactopyranoside (IPTG), ATP, GTP, CTP, UTP, cAMP, amino acids, rifampicin, 
formamide and 7-diethylamino-3-(4′-maleimidophenyl)-4-methylcoumarin (CPM) were 
obtained from Sigma-Aldrich (St. Louis, MO). Tris and SDS were obtained from Bio-
Rad Laboratories (Hercules, CA). [35S]-methionine (1000 Ci/mmol, 10 µCi/µL) was 
purchased from PerkinElmer Inc. (Boston, MA). Protease inhibitor (complete, EDTA-
free) was obtained from Boehringer Mannheim Corp. (Indianapolis, IN). T4 RNA ligase 
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and T4 polynucleotide kinase were purchased from New England Biolabs Inc. (Ipswich, 
MA).  Phosphorimaging analysis was performed using an Amersham Biosciences Storm 
820 equipped with ImageQuant version 5.2 software from Molecular Dynamics. UV 
spectral measurements were made using a Perkin-Elmer Lamdba 20 UV/vis 
spectrometer.  
 
4.4.2. Synthesis of N-petenoyl-phosphorotyrosine cyanomethyl esters 
 
 
4-pentenoyloxysuccinimide ester(4.19)25  
To a solution containing 5.0 mL (49.0 mmol) of pentenoic acid and 5.64 g (49.0 mmol)  
of N-hydroxysuccinimide in 100 mL CH2Cl2 was added 10.3 g (50.0 mmol) of N,Nʹ′-
dicyclohexylcarbodiimide. After stirring at room temperature for 2 hours, the reaction 
mixture was filtered and the filtrate was concentrated under diminished pressure. 
Crystallization of the crude product from ether-petroleum ether afforded 4-pentenoyloxy 
succinimide ester as colorless crystals: yield 7.63 g (79%); Rf 0.43 (1:1 ethyl 
acetate−hexane); mp 45-47 °C (47-48 °C). 
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N-pentenoyl-L-tyrosine cyanomethyl ester (4.8) 
To a solution containing 1.00 g (5.52 mmol) of tyrosine and 1.50 g (11.0 mmol) of 
K2CO3 in 15 mL of H2O (a few drops of 6 N NaOH were added for solubility) was added 
1.30 g (6.62 mmol) of 4-pentenoyloxy succinimide ester (4.19). The reaction mixture was 
stirred at room temperature for 16 hours. 80 mL of 1 N NaHSO4 was then added to the 
reaction mixture. The aqueous layer was extracted with three 125-mL portions of ethyl 
acetate. The combined organic extract was dried (MgSO4) and concentrated under 
diminished pressure. The crude product was then dissolved in 10 mL of acetonitrile; to 
the solution was added 4.6 mL (33.1 mmol) of triethylamine and 2.1 mL (33.1 mmol) of 
chloroacetonitrile. The reaction mixture was stirred at room temperature for 20 hours 
then diluted with 150 mL of ethyl acetate. The organic layer was washed with three 75-
mL portions of sat. NaHCO3. The organic layer was dried (MgSO4) and concentrated 
under diminished pressure. The crude residue was purified on a silica gel column (15 cm 
x 5 cm); elution with 1:1 ethyl acetate−hexanes afforded N-pentenoyl-L-tyrosine 
cyanomethyl ester (4.8) as a colorless solid: yield 1.03 g (62%); mp. 52-53 °C; Rf 0.45 
(1:1 ethyl acetate−hexane); 1H NMR δ 2.26-2.38 (m, 4H), 3.09-3.19 (m, 2H), 4.68, 4.79 
(ABq, 2H, J = 15.6 Hz), 4.91-5.06 (m, 3H), 5.72-5.84 (m, 2H), 7.12-14 (m, 2H) and 7.29-
7.35 (m, 3H); 13C NMR δ 14.1, 21.1, 35.2, 36.6, 49.0 53.3, 60.6, 114.1, 115.9, 126.1, 
130.3, 136.5, 156.0, 170.5, 171.7 and 173.3, mass spectrum (ESI) m/z 325.1 (M+Na)+ 
(theoretical m/z 325.1). 
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N-4-pentenoyl-phosphoro(1,2-dinitrobenzyl)-L-tyrosine cyanomethyl ester (4.11) 
To a stirred solution of 416 mg (0.95 mmol) of O-dinitrobenzyl-N,N-diisopropyl 
phosphoramidite and 92.0 mg (1.31 mmol) of tetrazole in 5 mL of anhydrous acetonitrile 
was added 107 mg (0.35 mmol)  of N-pentenoyl-L-tyrosine cyanomethyl ester (4.8). 
Following stirring for 30 minutes at r.t., a 5 M solution of tert-butylhydroperoxide in 
decane (262 µl, 1.31 mmol) was added. Following stirring for 10 minutes, the reaction 
mixture was diluted with 50 mL ethyl acetate and washed with three 30 mL portions of 
sat NaHCO3. The organic layer was dried (MgSO4) and concentrated under diminished 
pressure. The residue was purified by silica gel chromatography (15 cm x 5 cm); elution 
with 1:1 ethyl acetate−hexane afforded the phosphate product 4.11 as a yellow oil: yield 
138 mg (60%). 1H NMR δ 2.28-2.35 (m, 4H), 3.07-3.18 (m, 2H), 4.74 (ABq, 2H, J = 
12Hz), 4.88-4.93 (m, 1H), 4.97-5.05 (m, 2H), 5.61-5.63 (m, 4H), 5.72-5.82 (m, 1H), 6.04 
(d, 1H, J = 8 Hz), 7.11 (d, 2H, J = 8 Hz), 7.18 (d, 2H, J = 12 Hz), 7.51 (t, 2H, J = 8 Hz), 
7.66-7.74 (m, 4H) and 8.13 (d, 2H, J = 8 Hz); 13C NMR δ 29.6, 35.7, 49.3, 63.9, 114.4, 
117.3, 120.9, 120.8, 125.3, 128.8, 129.0, 131.0, 134.4, 147.2, 151.9, 170.7 and 172.5; 
mass spectrum (MALDI) m/z 540.3 (M+H-C7H7NO2)+ (theoretical m/z 540.1). 
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N-4-pentenoyl-phospho(1-nitrobenzyl-2-tert-butyl)-L-tyrosine cyanomethyl ester 
(4.12) 
To a stirred solution containing 272 mg (0.83 mmol) of O-1-nitrobenzyl-Oʹ′-tert-butyl-
N,N-diisopropyl phosphoramidite and 70 mg (0.99 mmol) of tetrazole in 2 mL of 
anhydrous ACN was added 100 mg (0.33 mmol) of N-4-pentenoyl-L-Tyrosine 
cyanomethyl ester. Following stirring for two days the reaction mixture was concentrated 
then re-dissolved in 10 mL DCM and washed with two 4-mL portions saturated NaHCO3, 
dried (MgSO4) and concentrated under reduced pressure. The phosphite was then 
dissolved in 2 mL anhydrous DCM and t-BuOOH (200 µL, 5M solution in decane) was 
added dropwise. Following stirring for 30 minutes, the reaction was diluted with 3 mL of  
DCM and washed with two 3-mL portions of saturated NaHCO3. The organic layer was 
dried (MgSO4) and concentrated under reduced pressure. The crude phosphate was then 
dissolved in 2 mL of anhydrous DCM followed by addition of 300 µL TFA. Following 
stirring for 30 minutes, the reaction was concentrated and the crude mixture was purified 
via preparitve HPLC (93:7 to 0:100 water/acetonitrile/0.1% TFA over 35 minutes, tR = 
24.3 min) to afford the product as a brown oil: yield 62 mg (36%); 1H NMR δ 2.3 (s, 4H), 
3.01-3.13 (m, 2H), 4.72 (ABq, 2H, J = 16 Hz), 4.85 (bs, 1H), 4.95-5.03 (m, 2H), 5.51-
5.55 (m, 2H), 5.68-5.80 (m, 1H), 6.35 (bs, 1H), 7.07 (d, 2H, J = 8 Hz), 7.13 (d, 2H, J = 8 
H
N O CN
O
O
O
PO O
O
NO2
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Hz), 7.47 (t, 1H, J = 16 Hz), 7.65 (t, 1H, 16 Hz), 7.76 (d, 1H, J = 8 Hz) and 8.11 (d, 1H, J 
= 4Hz); 13C NMR δ 29.1, 35.0, 36.7, 48.9, 52.9, 66.2, 66.3, 113.7, 115.9, 120.3, 120.4, 
124.9, 128.2, 128.7, 130.5, 132.5, 134.2, 136.3, 170.0 and 173.0; mass spectrum (ESI) 
m/z 518.1328 (M+H)+ (C23H25N3O9P requires 518.1329). 
 
4.4.3. Synthesis of phosporotyrosyl-pdCpA derivatives 
To a conical vial containing 1 equivalent of the tris(tetrabutylammonium) salt of pdCpA 
(TBA-pdCpA) in anhydrous DMF was added 5 eq. of N-4-pentenoyl amino acid 
cyanomethylester or NVOC-amino acid cyanomethylester and sonicated at room 
temperature. Following consumption of pdCpA, the reaction was purified by reverse 
phase HPLC using a gradient of 1%→65% acetonitrile in 50 mM ammonium acetate 
buffer (pH = 4.5) over 45 minutes. The appropriate fractions were collected and 
lyophilized to afford the product. 
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Mono-2'(3')-O-(dinitrobenzylphospho)-L-tyrosyl-pdCpA (4.14) 
The reaction was carried out as described above starting from 10.0 mg (7.4 µmol) of 
TBA-pdCpA and 24 mg (36.7 µmol) of compound 4.11 to afford monoaminoacylated 
pdCpA (4.14): tR 30 minutes; mass spectrum (ESI) m/z 1230.2360 (M-H)- 
(C47H51N11O23P3 requires m/z 1230.2372). 
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Mono-2'(3')-O-phospho-L-tyrosyl-pdCpA (4.15) 
1.3 mg (1.19 µmol) of 4.14 in 100 µL DMSO was irradiated using a Hg-Xe lamp at 0 °C 
for 5 minutes. Following irradiation HPLC analysis showed all starting was consumed 
and the solution was used directly in the ligation step without further purification. The 
new peak (tR 13 minutes) gave mass spectrum (ESI) m/z 960.1712 (M-H)- 
(C33H41N9O19P3 requires m/z 960.1737). 
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Mono-2'(3')-O-(nitrobenzylphospho)-L-tyrosyl-pdCpA (4.16) 
The reaction was carried out as described above starting from 5.0 mg (3.7 µmol) of TBA-
pdCpA and 9.5 mg (18.4 µmol) of 4.13 to afford monoaminoacylated pdCpA (4.16): tR 
18 and 19 minutes; mass spectrum (ESI) m/z 1095.2013 (M-H)- (C40H46N10O21 P3requires 
m/z 1095.2057).  
 
4.4.4. Synthesis of phosphoramidites 
 
Bis(2-nitrobenzyl)-N,N-diisopropylphsophoramidite (4.17)53 
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To a 0 °C cooled solution of dichloro(diisopropylamino)phosphine (5.0 g, 24.7, mmol) in 
20 mL of THF was added Hunigs Base (12.8 mL, 73 mmol) followed by 2-nitrobenzyl 
alcohol (7.56 g, 49.4 mmol) in 50 mL of THF. The reaction was allowed to stir at room 
temperature for 3 h. The precipitated solid was filtered and washed with 100 mL ethyl 
acetate. The organic phase was then wash with sat. NaHCO3 and NaCl. The filtrate was 
dried (MgSO4) and concentrated under diminished pressure to afford the product as a 
white solid:yield 5.3 g (53%); 1H NMR δ 1.23 (d, 12 Hz, J = 6.8 Hz), 3.67-3.77 (m, 2H), 
5.14 (dd, 2H, J = 7.6, 16.4 Hz), 7.42 (t, 2H), 7.64 (t, 2H), 7.85 (d, 2H, J = 7.6Hz) and 
8.08 (d, 2H, J = 7.6 Hz); mass spectrum (ESI) m/z 436.1638 
 (M+H)+ (C20H26N3O6P requires m/z 436.1638). 
 
 
O-2-nitrobenzyl-O-t-butyl-N,N-diisopropylphsophoramidite (4.18) 
To a 0 °C solution of PCl3 (4.37 mL, 50 mmol) in 150 mL of diethylether was added 
diethylamine (34 mL, 300 mmol) and the mixture was stirred for 8 h.  The reaction 
mixture was filtered and the filtrate was concentrated under diminished pressure. The 
residue was redissolved in 100 mL of THF and to the solution was added tetrazole (3.34 
g 49 mmol) followed by tert-butanol (4.75 mL, 50 mmol). The mixture was allowed to 
stir at room temperature for 5 hours under argon.  Nitrobenzyl alcohol (1 eq) was added  
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to the reaction and the mixture was left to stir overnight under argon. the solvent was 
concentrated under diminished pressure and the residue purified by silica gel flash 
chromatography (12 x 3 cm); elution with 97:3 hexane−triethylamine afforded the 
product was a yellow oil: yield 5.1g (31%); 1H NMR δ 1.06-1.10 (m, 6H), 1.38 (s, 9H), 
2.05-3.17 (m, 4H), 5.01-5.05 (m, 2H), 7.41 (t, 1H), 7.64 (t, 1H), 7.90 (d, 1H, J = 7.6 Hz) 
and 8.08 (d, 1H, J = 8 Hz); 13C NMR δ 15.2, 31.0, 37.9, 61.6, 75.4, 124.7, 127.7, 129.0, 
136.8 and 147.0; mass spectrum (MALDI) m/z 328.6 (M+H)+ (theoretical m/z 328.4). 
 
4.4.5. Synthesis of Fmoc-dinitrobenzyl-phosphorotyrosine 
 
 
Fmoc-dintrobenzylphosphotyrsoine (4.19) 
To a solution of 369 mg (5.26 mmol) of tetrazole and 868 mg (2.63) of O-dinitrobenzyl-
N,N-diisopropyl phosphoramidite in 25 mL of ACN was added 805 mg (1.75 mmol) of 
Fmoc-Tyr-OtBu. Following stirring for 12 hours the reaction was concentrated and the 
crude residue was solubilized in 40 mL of ethyl acetate. The organic phase was washed 
with three 40 mL portions of sat. NaHCO3, dried (MgSO4) and concentrated. The crude 
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phosphite was dissolved in 5 mL of anhydrous ACN and treated with t-butyl 
hyrdoperoxide (1.05 mL,5 M solution in decane). Following consumption of the starting 
material the reaction mixture was concentrated and the residue was dissolved in 40 mL 
ethyl acetate. The organic phase was washed with three 40 mL portions of sat. NaHCO3, 
dried (MgSO4) and concentrated. The crude residue was solubilized 5 mL of a 40% TFA 
solution in anhydrous ACN and stirred until the starting material was consumed. The 
reaction was then concentrated and re-solubilized in 40 mL ethyl acetate. The organic 
solution was washed with three 40 mL portions of saturated NaHCO3, dried (MgSO4) and 
concentrated. The crude residue was purified by preparative HPLC 95-5 water/ACN to 
60% acetonitrile over 40 minutes (tR = 30 minutes); 1H NMR δ 1.13-1.26 (m, 3H), 3.02-
3.06 (m, 2H), 4.03-4.10 (m, 2H), 4.26-4.28 (m, 1H), 4.35-4.39 (m, 1H), 5.53-5.54 (m, 
3H), 6.60 (d, 2H, J = 7.6 Hz), 6.84 (d, 2H, J = 7.6 Hz), 7.15-7.18 (m, 6h), 7.24-7.27 (m, 
5H) and 7.36-7.44 (m, 7H) 13C NMRδ 14.3, 20.8, 28.8, 37.1, 47.2, 54.6, 60.6, 120.1, 
125.2, 127.2, 128.6, 129.2, 131.1, 131.7, 133.6, 134.3, 141.4, 143.8, 146.8, 149.2, 155.9, 
174.2 and 176.6; mass spectrum (MALDI) m/z 753.9 (M+H)+ (theoretical m/z 753.7).  
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